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Welcome to the first CDC report on genomics and population health!   In this periodic report, we hope to present a timely and practical collection of vignettes of the status of genomics and population 
health in the United States. This information is intended for public health 
professionals who are interested in integrating genomics into health promotion, 
disease prevention and health care. The report includes information on what we 
know, what we don’t know and what is currently relevant in this rapidly evolving 
field. At the outset, we realize that many terms and concepts may be new and we 
therefore include a brief introduction to the “lingo” developed by the University of 
North Carolina at Chapel Hill. For your convenience, additional links to relevant 
Web sites and other resources are also available throughout the report. 
With the completion of the Human Genome Project in 2003, the stage has been 
set for an accelerated pace of discovery of thousands of genetic variants. Many 
variants will be studied for association with diseases of major public health 
importance, including adult chronic diseases, childhood conditions, infectious, 
environmental and occupational diseases. Applications of genetic information in 
diagnosis and prevention of various diseases must be driven by evidence on gene 
functions in normal and disease states as well as by the value of such information 
to improve health outcomes. In spite of the potential promise and excitement 
about human gene discoveries, there are still immense gaps in the knowledge 
needed for a successful translation of new research results into population health 
benefits. This “translation gap” calls for an important public health leadership 
role in applied research, policy development and integration of genomics into the 
practice of 21st century medicine. 
In this first report, we present some examples to show how public health is 
beginning to address three major gaps along the genomics “translation highway”: 
1. Conducting genomics and population health research, 
2. Developing evidence on the value of genomic information, and 
3. Integrating genomic information in practice and programs. 
Foreword 
Muin J. Khoury 
Public Health Professional 
A person educated in public 
health or a related discipline 
who is employed to improve 
health through a population 
focus. 
(Who Will Keep the Public Healthy? 
Educating Public Health Professionals 
in the 21st Century, IOM, 2003, p. 30) 
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1. Conducting genomics and population health research. 
Most human disease results from interaction between inherited genetic variations 
and numerous environmental factors (e.g., diet, infections, lifestyle, chemicals 
and social factors). With the thousands of genetic variants discovered, there is 
a real urgency to characterize what genetic variation means for health, to assess 
the prevalence of genetic variants in different populations, and to examine their 
contribution to the population burden of disease, death and disability. In this first 
report, we highlight two current CDC efforts in this area. The first example (Chapter 
1) is a project to evaluate the prevalence of 57 genes and their variants in a nationally 
representative sample of the United States population. We provide an overview of 
the criteria used to select these genes for study and a description of the planned 
project. The second example (Chapter 2) discusses the potential for examining the 
role of human genomics in the setting of acute public health investigations, a 
mainstay of public health efforts to characterize and prevent disease occurrence in 
communities with acute health problems or a disproportionate burden of disease. 
2. Developing evidence on the value of genomic information. 
To use genetic information successfully in population-level programs and individual 
management of patients, we need solid scientific evidence to help guide policy 
development and guideline recommendations. In this report, we review the 
public health implications of the evolving asthma genomics research, including 
pharmacogenomics, the new targeting of drug therapies to specific genotypes 
(Chapter 3), as well as the evolving evidence and guidelines about genetic testing 
for breast and ovarian cancer (Chapter 4). We also discuss the example of MCADD 
to describe an emerging area of newborn screening using the new technology of 
tandem mass spectrometry, which is increasingly adopted in state public health 
programs (Chapter 5). We also highlight a CDC initiative to develop and evaluate 
family history tools for augmenting chronic disease prevention efforts (Chapter 6). 
We ask critical questions about the role of “genetic profiling” tests that are being 
promoted for preventing coronary heart disease and determine whether or not such 
tests are ready for prime time (Chapter 7), and review ethical, legal and social issues 
(Chapter 8). 
3. Integrating genomic information in practice and programs. 
Because health professionals are most concerned with practice and programs, this 
section of our report is the longest. To integrate genomic information into practice 
and programs, we need a competent workforce, a robust health system, and an 
informed public. We need careful policy development and planning that recognizes 
the complexity of genomics issues while building on approaches that have been 
successful in evaluating other health related technologies. We provide an update 
on efforts to ensure the quality of genetic testing (Chapter 10). We also provide 
timely and relevant practice information for two specific conditions: hereditary 
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hemochromatosis (Chapter 11) and cystic fibrosis (Chapter 9). We cover training 
issues (Chapter 12), genomic tools for public health (Chapter 13), issues related to 
state genetic planning (Chapter 14), and provide Internet-based resources (Chapter 
15). 
We hope that the topics chosen for this report reflect emerging common interests 
and concerns. We have tried to present population-based data when available, 
describe potential applications to public health and prevention practice, and 
offer value-added interpretation. The report is based on a collaboration of many 
individuals and programs at CDC and other partners. We are indeed very thankful 
for their efforts. 
We would like to invite readers to give us feedback on this first report, to help us 
improve future editions. Please use the comments card found in this report or visit 
our Web site: (http://www.cdc.gov/genomics/activities/ogdp/2003.htm). Current 
information on the application of genomics in public health is still sparse and 
contains many gaps; however, we hope that increasing experience at the state and 
community levels will help to fill these gaps over time. We hope that the data and 
information contained in these reports will prove useful in guiding public health 
research, policy and practice in order to help reap the benefits of the Human 
Genome Project for citizens in the 21st 
3 
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A Year at a Glance 

Help With the Lingo… 
What Do the Terms Mean?
Elizabeth Mahanna 
Genetics vs. genomics 
refers to the study of single genes, while genomics refers to the study of all the 
DNA. 
“Sequencing the genome” is another buzz phrase that has gotten a lot 
of press 
Human Genome Project “sequenced the entire human genome.” Sequencing 
refers to a detailed description of the order of chemical building blocks of DNA. 
Human DNA is made up of billions of these building blocks, called bases. 
Backtracking for a moment… what is the relationship between DNA, 
bases, genes, and chromosomes? 
The chemical DNA 
contains chemical building blocks called bases
Genes 
are pieces of DNA that contain instructions for making cells or for what cells do. 
Each gene contains instructions for building one or more proteins, but a gene can 
contain millions of bases, so deciphering how it works or what a mutation is can 
mutation is a change in the order of the bases in a gene. 
gene contains instructions for building proteins, and the genome can be thought 
piece of DNA, but rather it is divided into separate pieces, called chromosomes. 
Each chromosome has many genes—between 231 (Y chromosome) and 2968 
The two terms are sometimes used interchangeably. However, genetics usually 
genes in a person or organism. The human genome is a person’s complete set of 
Perhaps you heard the announcement back in April 2003 that scientists at the 
(deoxyribonucleic acid) is in all the cells of our body. It 
. There are only four bases (A, T, 
G and C) but they repeat in an ever-changing order throughout our genes. 
be very difficult. A 
Amazingly, genes make up only about 2% of the human genome—the rest are 
regions that do not make instructions as genes do. It is currently thought that we 
have between 30,000 and 40,000 genes (only twice as many as a fruit fly). Each 
of as the complete book of instructions. The genome is not one extremely long 
(chromosome 1). We have 46 chromosomes in 23 pairs. One chromosome in each 
pair we inherit from our father, and one in each pair we inherit from our mother. 
We have two nearly-identical copies of every gene, with the exception of those on 
7

the “sex” chromosomes, named X and Y. Females have two X chromosomes and 
males have an X and a Y. 
It’s the proteins 
Actually, it’s not the genes that carry out instructions for the body’s cells—it’s the 
proteins. Each gene “codes for” or makes a protein or proteins. The proteins do 
the work in the body. Through these proteins, our genes control how we process 
foods, detoxify poisons, respond to infections, and the like. Humans can make at 
least 100,000 different kinds of proteins. Ever heard the word “proteomics”? It’s 
the science of figuring out these proteins. 
We are 99.9% the same 
Scientists have found that, of the 3 billion or so bases in the human genome, 
99.9% are exactly the same from person to person. About 3 million (or 0.1%) are 
different, and that’s what makes us unique. Three million may seem like a big 
number, but it’s not much compared to 3 billion. Scientists now think that there 
are more genetic differences between people of the same race than between people 
of different races. 
Disease is a result of the interaction between genes and environment 
This is true for almost all diseases. The word “environment” encompasses many 
things. It includes what you eat, your lifestyle and habits (smoking, alcohol use, 
exercise, etc.), and what chemicals you may have been exposed to (including 
medications). It also includes your physical environment such as climate or sun 
exposure and psychological factors such as stress. Environment pretty much 
includes everything that is not genetic. 
Changes or mutations in genes, for the most part, do not cause disease. They 
influence a person’s vulnerability to things in the environment. If we inherit 
“mutated” genes from our parents, we do not inherit disease—we inherit an 
increased susceptibility risk for certain diseases. We’ve all heard of the people 
that exercised all their life, watched their cholesterol and ate healthy meals—and 
dropped dead of a heart attack at age 40. We’ve also heard of the people who 
smoke, drink, have an unhealthy diet, and live to be 100. Most people fall 
somewhere between those two extremes. 
Most common diseases, such as cancer, heart disease, and diabetes, result from 
a complicated interaction between several genes and the environment. A few rare 
diseases (such as Huntington’s or Tay-Sachs disease) are disorders that arise from 
a single gene and do not appear to have an environmental component. These 
diseases account for a very small proportion of human disease. Other single-gene 
disorders are greatly affected by environment, such as hereditary hemochromatosis or PKU. 
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Many people tend to classify a disease as either genetic or environmental. For 
example, Uncle Harold smoked all his life and died of lung cancer. Smoking 
obviously caused his lung cancer. However, only 10-15% of smokers will develop 
lung cancer. So there must be something else going on—most likely variations in 
people’s genes that either predispose them to getting cancer or protect them from it. 
Modified from the University of North Carolina at Chapel Hill, School of Public Health, 
Web site: http://www.sph.unc.edu/nciph/phgenetics/index.htm. This Web site was made 




National Health and Nutrition 
Examination Survey
(NHANES) III DNA Bank:
Gene Variants Important to 
Public Health
Mary Lou Lindegren for the NHANES CDC-Wide Working Group 
NHANES III DNA Bank 
The National Health and Nutrition Examination Survey (NHANES) is a nationally 
representative survey of the United States population, conducted by the National 
Center for Health Statistics (NCHS).1 Detailed interviews, clinical, laboratory and 
radiological examinations are conducted as part of the survey. NCHS has collected 
these data with an assurance of confidentiality. 
During the second phase of NHANES III (1991-1994),2 white blood cells were 
frozen and cell lines were immortalized with Epstein-Barr virus, creating a DNA 
bank. 3 The bank is maintained by the National Center for Environmental Health, 
CDC, and contains specimens from more than 7000 participants. In 2002, NCHS 
requested proposals for the use of these specimens.4, 5 
Collaborative CDC-Wide Project 
A CDC-wide working group of epidemiologists and laboratorians, representing 
most Centers and Institutes at CDC, was convened to develop a collaborative 
proposal for determining the prevalence of selected genotypes of public health 
importance using the NHANES III DNA Bank. 
Selecting Genetic Variants Important to Public Health 
The criteria used to select genes for the proposal included: 




•	 role in pathways affecting multiple diseases, 
•	 identified functional variants, 
•	 relatively common variants (prevalence >2%), 
•	 previously described gene-environment or gene-gene interactions, 
•	 relevant phenotypic data available in NHANES datasets, and 
•	 no current use for clinical risk assessment or intervention. 
11 
Prevalence 
The number of people with 
a trait or condition at a 
specific point in time. 
Gene Variant 
A variation in the sequence 
most commonly observed for 
a particular gene. 
Genotype 
The genetic make-up of an 
individual. 
Phenotype 
The observable traits 
or characteristics of an 
individual. 
Several challenges that made this process difficult were: 
•	 gaps in published information, 
•	 many available studies demonstrated problems with methodology, 





•	 non-replication of many published gene-disease associations. 
The final proposal included 87 variants of 57 genes known to be important in at 
least six major pathways: 
•	 nutrient metabolism (e.g., folate and homocysteine; lipids; glucose; 
alcohol; vitamin D), 
•	 immune and inflammatory responses (e.g., cytokines, cytokine receptors), 




•	 DNA repair pathways (e.g., ionizing radiation, environmental toxins), 
•	 hemostasis and renin/angiotension pathways, and 
•	 developmental pathways. 
Genotyping will be performed in collaboration with the National Cancer Institute 
(NCI) at the NCI Core Genotyping Facility. 
Potential Value for Public Health 
Prevalence data from the NHANES database will be the basis for future 
analysis of gene-disease associations and gene-environment interactions. 
Gene-environment interactions are considered to be the fundamental 
biological processes that both maintain health and bring about disease. As our 
understanding of these interactions grows, establishing the prevalence of gene 
variants known to interact with specific environmental factors will be a key 
factor in assessing the potential impact of environmental interventions. Genotypic 
information will add another dimension to the analysis of clinical, physical, and 
lifestyle information collected by NHANES. Additional analysis of genotype-




Association with Body Burden of Cotinine 
This proposal involves correlating over 40 
or (pronounced “snips”) in 14 genes involved in drug-nicotine 
metabolism and smoking behavior with serum cotinine measurements already 
This proposal will evaluate the individual and joint effects (interactions) of 
selected common polymorphisms of three genes in the folate metabolism 
pathway and the consumption of folic acid on homocysteine and folate levels. 
NCBDDD National Center on Birth Defects and Developmental Disabilities 
NCHSTP 
NCID National Center for Infectious Diseases 
NCEH National Center for Environmental Health 
NCCDPHP National Center for Chronic Disease Prevention and 
Health Promotion 
NIOSH National Institute for Occupational Safety and Health 
NIP National Immunization Program 
NCHS National Center for Health Statistics 
OGDP 
PHPPO 
Two Other CDC Projects Using NHANES III DNA Samples 
Prevalence of Gene Variants that Code for Enzymes Involved in Nicotine 
and Carcinogen Metabolism in the United States Population and their 
Karen Steinberg, et al. 
Single Nucleotide Polymorphisms 
SNPs 
performed, and with self-reported smoking variables. 
Frequency of Common Genotypes of Folate-Related Genes and their Effect 
on the Relation between Intake and Blood Levels of Folate and Homocysteine 
Lorenzo Botto, et al. 
NHANES CDC-Wide Working Group 
http://www.cdc.gov/genomics/NHANES.htm 
ATSDR Agency for Toxic Substances and Disease Registry 
National Center for HIV, STD, and TB Prevention 
Office of Genomics and Disease Prevention 
Public Health Practice Program Office 
Single Nucleotide 
Polymorphism – SNP 
Common, but minute, 
variations that occur in 
human DNA at a 
frequency of one in 
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20038-filed. Accessed Feb 18, 2004. 
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Chapter 2
Genomics and Acute 
Public Health Investigations
health events followed by rapid application of prevention and control measures. 
local health departments, as well as the health ministries of other nations, often 
a particular acute public health problem. These investigations typically evaluate 
through federal, state and local public health partnerships have earned the public 
health system both national and global recognition. 
Incorporating Human Genomics into APHIs 
The translation of genomic information for public health research and practice 
presents a unique opportunity for enhancing APHIs. As our knowledge of the role 
of human genomics in human susceptibility and disease causation increases, so 
does its potential to sharpen our response to acute public health events. Health 
investigations where human genomics may be important include: 
• disease clusters (e.g., infectious disease outbreaks, cancer or birth defect 
clusters), 
• 
• adverse reactions to therapeutics (e.g., vaccines, antibiotic prophylaxis and 
blood products). 
resources. Investigations that could incorporate human genomics need to be 
factors and the disease, etc.) Resources also must be evaluated, as there may be 
challenges involved in sample collection, specimen and data banking, genomic 
testing, and possible delays (due to protocol review or increased demands on 
participants and investigators). 
Jairam Lingappa and Mary Lou Lindegren 
What is an Acute Public Health Investigation (APHI)? 
An Acute Public Health Investigation (APHI) is a timely assessment of adverse 
APHIs use epidemiological and laboratory methods, and have long been 
recognized as the responsibility of the nation’s public health system. State and 
invite CDC to assist in field investigations to determine the cause and extent of 
demographic, behavioral and exposure-related risk factors. APHIs accomplished 
exposure clusters (e.g., environmental, occupational and bioterrorism), and 
The decision to collect human genomic information during an Acute Public 
Health Investigation must be informed both by scientific potential and by available 




The science of managing and 
analyzing biological data 
using advanced computing 
techniques; especially 
important in analyzing 
genomic research data. 
Incorporating human genomics into APHIs has great potential to benefit public 
health, including opportunities to learn more about diseases that occur largely 
in epidemic settings (e.g., cholera, SARS), or as a result of mass exposure to 
rare threats (e.g., toxic releases, anthrax), or where interventions could be more 
effectively targeted or genomic tools more efficiently utilized. In addition, as 
detailed exposure data is often collected during an APHI, the incorporation 
of human genomics would allow for the assessment of gene-environment 
interactions. Finally, banked specimens from AHPIs may provide a key resource for 
addressing long term research questions about human genomic factors in relation 
to disease causation and prevention interventions. 
Research approaches that could lead to enhanced prevention, detection and 
control of future adverse health events include the assessment of: 
•	 genomic profiles (e.g., relation to susceptibility, resistance, severity, 





•	 exposure profiles (e.g., the use of mRNA transcripts to estimate exposure 
levels or characterize exposure), and 
•	 outcome variation (e.g., the use of protein expression to characterize 
outcomes). 
This information may aid in identifying causes of adverse health events and 
directing public health and clinical interventions, such as vaccination, exposure 
reduction, behavioral intervention, and therapeutics. 
APHI Working Group 
CDC has formed a multidisciplinary APHI Working Group in collaboration with 
the Council of State and Territorial Epidemiologists (CSTE) to develop a plan and 
tools for incorporating genomics into APHIs. The Working Group will engage 
state public health departments and other partners to address several core areas: 
•	 science – selection of genes and gene pathways for study; 
•	 technology – collection, storage, processing and banking of biologic 
specimens, technologies for human genomic testing, database issues and 
bioinformatics; 
•	 epidemiology and statistics – study design, implementation, and analysis; 
•	 ethical, legal, and social implications (ELSI) – informed consent, 





The Working Group is planning a workshop in 2004, and is inviting external 
consultants who will provide additional expertise and guidance for developing a 
research agenda for including human genomics in APHIs. Workshop participants 
will offer input on priority research areas such as: 
•	 assessing criteria for prioritizing investigations that should incorporate 
human genomics, 
•	 identifying information gaps and needs, 
•	 developing standard tools and protocols for the field and laboratory work 
as well as the informed consent process, 
•	 making tools available to epidemiologists and public health officials 
involved in the acute public health investigation, 
•	 creating educational materials for the public health workforce both within 
CDC and with the states involved in APHIs, and 
•	 developing pilot studies and just-in-time protocols. 
Conclusion 
The genomics revolution can refine our ability to conduct effective investigations 
of acute public health events. Enhancing our understanding of disease 






Implications for Public Health
What Causes Asthma? 
disproportionately in children and minorities, and prevalence has increased 
both genetic and environmental contributors to the development of asthma. 
Public Health Implications of Asthma Genomics Research 
Center for Genomics and Public Health, organized an evaluation of the 
implications of asthma genomics research for public health. Based on an initial 
four areas of potential action in which genomic research or information might 
contribute to public health efforts to reduce asthma morbidity and mortality: 
• population-based prevention, 
• targeted prevention based on risk status, 
• diagnosis, and 
• management. 
potential interventions: 
Tabitha Harrison, Karen Edwards, and Wylie Burke 
Asthma is a chronic lung condition characterized by airway inflammation, 
airway hyper-reactivity and reversible airway obstruction. The disease is found 
significantly since the early 1980s. No single factor is responsible for the 
development of asthma. Environmental exposures, such as house dust mites, 
fungal spores, cockroaches, tobacco smoke, and animal dander have been 
identified as contributors. In addition, as early as the 1920s, studies demonstrated 
the existence of a familial predisposition to asthma. There is strong evidence for 
In 2003, the Asthma Working Group, created by the University of Washington 
literature review and discussion, the UW Asthma Working Group identified 





of multiple gene 
variants associated 
with predisposition to a 
particular disease. 
Pharmacogenomics 
Refers to the use of genomic 
techniques to enhance drug 
development and define 
drug responses. 
•	 patient and family, 
•	 community, 
•	 researcher, 
•	 health care professional, and 
•	 public health practitioner. 
The plan for expert consultation sought feedback on these potential areas 
of intervention and important considerations from each of the identified 
perspectives. A sixth perspective—that of the commercial developer—was added 
based on comments made during the consultation. 
The first round of consultation made use of asthma expertise available in the 
Seattle community and in Washington State. Subsequent rounds of consultation 
sought advice from: 
•	 experts at the University of Michigan Center for Genomics and Public 
Health and the University of North Carolina Center for Genomics and 
Public Health, 
•	 national experts identified through consultation with local and federal 
advisors, and 
•	 experts attending the American Thoracic Society meeting (Seattle, May 
2003) and the National Conference on Asthma 2003 (Washington DC, 
June 2003). 
Experts were interviewed individually or in small groups; most experts also 
identified additional relevant medical literature. Over the course of the 
consultation and literature review, some common themes emerged. These included 
the potential role of genomic profiling as a means for identifying individuals with 
increased asthma risk; the implications of commercial incentives for technology 
development; the relevance of current data on behavioral interventions, treatment 
adherence and clinical outcomes for potential genome-based interventions; and 
the significance of current data related to differences in asthma prevalence across 
demographic groups for public health research and actions. 
Pharmacogenomics and Predictive Testing 
Consultants consistently identified pharmacogenomics as the area of genomic 
research most likely to change asthma care in the near future. Genetic factors 
have been estimated to account for 60% to 80% of the variability in asthmatics 
patients’ response to medications.1 Genomic strategies will aid in the identification 
of new drug targets, and may lead to drugs designed for use in specific subsets of 
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asthmatic patients, defined by genotype. In addition, pharmacogenomic research 
will produce genetic tests designed to predict drug responses and adverse side 
effects. 
In the long term, genomic research may also produce genetic tests that will aid 
in disease classification, predict prognosis, or identify unaffected children who 
are at increased risk to develop asthma. One possible application of the latter 
capability would be newborn testing, to identify infants who might benefit from 
environmental modifications or immunotherapy for prevention. While such 
research holds promise for innovative treatments and effective prevention, it will 
not succeed without careful attention to the interaction between genetic and non-
genetic contributors to asthma. 
Public Health Actions —Asthma Genomics Research 
Actions on the part of public health can help to ensure that genomic research 
supports public health goals to reduce asthma morbidity and mortality. These 
include: 
•	 On-going critical evaluation of research on genetic contributors to asthma, 
to guard against overly simplistic interpretation of data addressing genetic 
hypotheses. Headlines proclaim the discovery of “the gene for disease 
X”, without much attention to the complex etiology of diseases such as 
asthma.2 Researchers and practitioners concerned about the public health 
implications of asthma research need to be vigilant against the over-
interpretation of genetic data, or an overly ready assumption of genetic 
causes for observed differences. 
•	 Funding and advocacy, to ensure that evidence gaps are addressed with 
appropriate research strategies. In particular, public health input will 
help to ensure adequate selection and definition of study populations, 
meaningful measures of environmental exposure, and inclusion of 
appropriate clinical outcomes. 
•	 Participation in design of recruitment and data management strategies for 
population-based genomic research. CDC and state public health agencies 
could play an important role in crafting public messages and recruitment 
strategies to ensure adequate participation in population-based studies, 
and in developing policies for data collection and management that reduce 
fears about inappropriate uses of genetic information. 
•	 Support for evidence-based practice in pharmacogenomics and genetic 
testing, including rigorous assessment of the utility and cost-effectiveness 
21 
of drugs requiring prior testing to determine candidacy for treatment, and 
of genetic tests proposed as a means to tailor drug regimens or predict 
future disease.3 
•	 Advocacy to ensure access to genomics-based therapies for the medically 
underserved, when they are found to be cost-effective. 
•	 Utilization of the convening power of public health, to foster 
multidisciplinary collaboration in research and broad stakeholder 
participation in the development of research and clinical practice policies. 
In order to accomplish these goals, public health will need an infrastructure for 
technical support, consultation, and education. The most efficient approach is 
likely to involve an incremental development of expertise, starting with a small, 
centralized, multidisciplinary group that works in partnership with designated 
state liaison persons and academic centers conducting research in public health 
genetics. 
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Chapter 4
Public Health Assessment of 
BRCA1 and BRCA2 Testing for 
Breast and Ovarian Cancer
Monica R. McClain, Glenn E. Palomaki, Linda A. Bradley, and Ralph J. Coates 
Breast and Ovarian Cancer: An Important Public Health Problem 
Breast cancer is the most common form of cancer in United States women 
(approximately 216,000 new cases will be diagnosed in 2004), and the second 
most common cause of cancer deaths (approximately 40,000 deaths per year).1 
Ovarian cancer is less common (about 25,000 new cases each year), but about 
three-quarters of cases are diagnosed at a late stage, when it is often fatal. Each 
year, an estimated 809,000 person-years of life are lost due to breast cancer, and 
232,000 person-years are lost due to ovarian cancer.2 
Genetic Tests for Breast and Ovarian Cancer Susceptibility 
Most breast and ovarian cancers occur after menopause, and the risk increases 
with age. Because most symptoms and clinical signs of breast cancer are relatively 
specific and well understood, an early diagnosis is possible through established 
mammography screening programs. Ovarian cancer signs and symptoms are 
not apparent in the early stages and routine screening is not recommended for 
the general population. Diagnosis of breast or ovarian cancer is by biopsy and 
pathologic examination. 
Two genes, BRCA1 and BRCA2 (BReast CAncer genes), are associated with 
predisposition to hereditary breast or ovarian cancer. Mutations in these genes are 
identified in 1-2% of women with breast cancer and 5-10% of women with ovarian 
cancer.3 A prominent characteristic of these inherited cancers is early age at onset. 
Women identified with a BRCA1 or BRCA2 mutation have a substantially increased 
risk of developing breast and/or ovarian cancer during their lifetime. These risks are 
compared with those in the general population in the following table: 
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Table 1. Risks of Developing Breast and Ovarian Cancer by Age 70 in the 
General Population Compared with Women with a BRCA1 or BRCA2 
Mutation 
By Age 704 
(%) 
or 
Mutation Risk By Age 
703(%) 
Breast Cancer 9.7 35 – 85 
Ovarian Cancer ~ 1 9 – 66 
General Population Risk BRCA1 BRCA2 Cancer Type 
The two BRCA genes have been patented. As a result, one laboratory performs 
most clinical testing for BRCA mutations in the U.S. and the test itself is 
trademarked under the name BRACAnalysis™. Comprehensive BRCA analysis is 
one form of the test that examines the full sequence of the BRCA1 and BRCA2 
genes to look for mutations that indicate a predisposition to hereditary breast and 
ovarian cancer. 
A Public Health Perspective 
Genetic testing for BRCA1 and BRCA2 mutations is a complex process and is 
not recommended for women in the general population. At present, BRCA1 and 
BRCA2 mutation testing may be appropriate for only a small proportion of women 
(less than one percent). These women can make an informed decision about 
testing in collaboration with their health care providers. An informed decision 
requires that the potential benefits and potential risks or limitations of testing are 
considered. 
The Role of Family History in BRCA1 and BRCA2 Testing 
The first step in considering BRCA1 and BRCA2 mutation testing for adult women 
is to ask about the woman’s family history of breast and ovarian cancer because: 
•	 most breast and ovarian cancers are not inherited, but occur sporadically; 
•	 BRCA1 and BRCA2 mutations are uncommon (about 1 in 400 women 
carry a mutation); 
•	 the cost of full genetic testing (Comprehensive BRACAnalysis) is nearly 
$3000; 
•	 women with a strong family history are more likely to have a mutation. 
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http://www )
Screening women by asking their family history is relatively inexpensive and 
identifies families in which the chance of finding a BRCA1 or BRCA2 mutation is 
at least 10%. It does, however, have disadvantages: 
•	 there is no standard definition of a positive family history for breast/ 
ovarian cancer; 
•	 about half of the women who carry a BRCA1 or BRCA2 mutation will not 
have a positive family history;3 
•	 in most families with a positive history of breast and ovarian cancer, 

BRCA1 and BRCA2 mutations are not involved;3,5

•	 some types of mutations in the BRCA1 or BRCA2 genes are not detectable 
by the methodology used for Comprehensive BRACAnalysis. 
The Role of Genetic Counseling in BRCA1 and BRCA2 Testing 
Organizations commonly recommend that when a woman considering BRCA1 
and BRCA2 mutation testing has a family history suggestive of inherited breast 
and ovarian cancer, she should consult with a genetic counselor or other provider 
with experience in cancer genetics.6,7 The decision to undergo genetic testing is 
complicated and involves understanding the nature and risks of breast and ovarian 
cancers and the risks, benefits and alternatives to genetic testing. Women will 
need to consider these issues along with their preferences and values.8 
The process of genetic counseling is designed to assist in: 
•	 understanding the test and its limitations, 
•	 understanding medical facts, 
•	 understanding the hereditary contribution to the disorder, and 
•	 choosing the course of action that is appropriate, based on level of risk, 
family goals, and ethical and religious beliefs. 
Resources are available to assist health care providers and patients in locating 
genetic counseling services in their area (e.g., .nsgc.org . 
BRCA1 and BRCA2 Mutation Testing 
If the woman seeking genetic testing has not had breast or ovarian cancer, 
organizations that support genetic testing recommend that a family member with 
cancer be tested first.6 If a mutation is not found, testing of other family members 
is not warranted. If a mutation is detected, subsequent testing of family members 
is simpler (and cheaper) because testing is focused on the identified mutation. 
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Family members found to have the identified mutation are at increased risk 
for developing breast or ovarian cancer. Family members who do not have the 
identified mutation have the same risk for developing breast or ovarian cancer as 
members of the general population with similar demographic and environmental 
characteristics. 
If mutation testing cannot be performed on an affected family member, further 
genetic testing of family members may not be warranted because the test results 
might not be informative. For example, finding no mutations in a woman who 
does not have cancer does not distinguish between the possibilities that: 
1.	 she did not inherit a BRCA1 or BRCA2 mutation that caused cancer in 
other family members, or 
2.	 the increased risk of cancer in her family is not caused by a detectable 
BRCA1 or BRCA2 mutation. 
If a woman is found to have BRCA1 or BRCA2 mutation, she may benefit because 
she knows she is at higher risk and she may choose some medical options 
discussed in the following section. Finding a mutation prompts several additional 
considerations: 
•	 Carrying a mutation may present psychological and social dilemmas, and 
introduce the potential for employment and/or insurance discrimination. 
•	 Males can also carry a BRCA1 or BRCA2 mutation. In males, mutations in 
BRCA1 and BRCA2 have been associated with an increased risk of male 
breast cancer (especially BRCA2 mutations) and prostate cancer. 
•	 Approximately 13% of Comprehensive BRACAnalysis tests report a variant 
of “uncertain clinical significance”.9 This means that it is unknown whether 
or not these variants are associated with increased cancer risk, so that the 
woman will not know if her test result signifies an increased risk of cancer. 
Surveillance and Risk-Reducing Strategies for Breast and Ovarian 
Cancer 
Organizations that recommend testing and genetic counseling also recommend 
surveillance for women who choose not to have risk reducing surgeries. 
Breast Cancer Surveillance by Mammography and/or Magnetic Resonance 
Imaging (MRI): 
•	 Increased surveillance for early breast cancer detection is acceptable to at 
least half of women with a BRCA1 or BRCA2 mutation.3 
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•	 In women with BRCA1 or BRCA2 mutations, surveillance will identify 
about two-thirds of the breast cancers.3 
•	 How effective breast cancer surveillance is in reducing mortality in women 
with a BRCA1 or BRCA2 mutation is not known. 
•	 The false positive rate of breast cancer surveillance in women with a BRCA1 
or BRCA2 mutation is not known. 
Ovarian Cancer Surveillance by Serum Tumor Markers and/or Ultrasonography: 
•	 Increased surveillance for ovarian cancer detection is less acceptable than 
breast cancer surveillance in women with a BRCA1 or BRCA2 mutation.3 
This is likely because the effectiveness of these tests in detecting cancer 
and reducing mortality is uncertain.3 
•	 About 4% of women who undergo surveillance for ovarian cancer will have 
a false positive result —that is, they will also have exploratory surgery that 
does not detect ovarian cancer.3 
Risk-Reducing Surgeries 
Risk-reducing surgeries are the most effective means of preventing breast and/ 
or ovarian cancer. While women with BRCA1or BRCA2 mutations who choose 
preventive mastectomy (surgical removal of breast tissue) may reduce their risk 
of breast cancer by at least 90%, acceptance of this option is 15% or less in 
the U.S.3 Oophorectomy (surgical removal of the ovaries) may reduce the risk 
of breast cancer by about half and the risk of ovarian cancer by nearly 100%.3 
Oophorectomy has higher acceptance (13-50%, depending on the study) among 
BRCA mutation carriers, particularly those over age 40 (64-78%).3 
Chemoprevention 
Chemoprevention of breast cancer is another option, but is less acceptable to 
women regardless of mutation status, possibly due to side effects such as blood 
clots.10 In one study, only 5% of all women accepted treatment by tamoxifen.11 
There is also some uncertainty about the effectiveness of tamoxifen in reducing the 
risk of breast cancer in women who carry BRCA1 or BRCA2 mutations.12,13 
Lifestyle Changes 
Although excess body weight and physical inactivity may be responsible for about 
one fourth to one third of breast cancers in women in the general population,14 
the effects of lifestyle modifications (e.g., diet, exercise, not smoking) in BRCA1 
and BRCA2 mutation-positive women have not been directly studied. Patients at 
increased risk may welcome the opportunity to be in control of these aspects of 
their lives and may enjoy improved health. 
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Evaluation of BRCA1 and BRCA2 Testing in Practice 
Although at least four organizations have issued guidelines on the use of BRCA1 
and BRCA2 mutation testing for breast and ovarian cancer susceptibility in the 
U.S.,3 no one set of guidelines has been universally accepted and implemented in 
clinical practice. This is due in part to the small amount of information available 
to assess how well the test identifies women who may benefit from testing and 
how effective and acceptable the interventions are. Other reasons may include the 
complexity of implementing and interpreting family history questionnaires. See 
Chapter 10, Ensuring the Quality of Genetic Testing in the United States, for more 
information. 
Understanding the public health impact of genetic tests also requires the 
collection of data to investigate performance in practice, as well as quality, 
utilization and access. Collaboration between public health agencies, clinical care 
providers, professional organizations, and industry will be needed to collect this 
information. Related projects supported by CDC include: 
•	 an evidence-based ACCE Review on BRCA1 and BRCA2 mutation testing 
in women with a family history of breast/ovarian cancer (ACCE is a model 
process for evaluating data on genetic tests; see http://www.cdc.gov/genomics/ 
activities/fbr.htm), 
•	 a study by the U.S. Preventive Services Task Force to examine the clinical utility 
of BRCA1 and BRCA2 mutation testing, funded by the Division of Cancer 
Prevention and Control, National Center for Chronic Disease Prevention and 
Health Promotion, CDC, and 
•	 a study to determine the impact on knowledge, attitudes and actions of a 
direct-to-consumer advertising campaign about BRCA1 and BRCA2 mutation 
testing that targeted women and their health care providers in two pilot cities, 
Atlanta, GA and Denver, CO. 
Effectiveness of BRCA1 and BRCA2 Testing for Prevention 
•	 Overall, BRCA1 and BRCA2 mutations are responsible for only a few percent of 
breast and ovarian cancers, but effective risk-reducing strategies are available. 
•	 Access to these risk-reducing strategies may be limited by lack of insurance or 
inadequate coverage, failure of health care providers to appropriately refer, or 
availability of services in certain areas. 
•	 Limited information is available about implementation issues surrounding the 
use of a routine family history plus BRCA1 and BRCA2 mutation testing strategy. 
Limited information is also available about the economic consequences. 
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http://www.cancer.org/downloads/MED/P . Accessed Mar 29, 2004.
•	 Acceptance of mutation testing is also limited by other issues, such as adverse 
health consequences of some prevention strategies and social stigmatization. 
Conclusion 
Genetic testing for BRCA1 and BRCA2 mutations may be appropriate for 
individuals with specific family histories of breast and/or ovarian cancer. There are 
many issues that must be considered throughout the testing process in order for 
an individual to make an informed decision regarding testing. 
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Chapter 5
Newborn Screening for MCAD 
Deficiency
Autosomal Recessive 
Inheritance of two copies 
of a mutant gene, one from 
each parent, on one of the 
22 autosomes (chromosomes 
other than X or Y). 
Mary Dott, Roberta C. M. Wines, Barbara Adam, and Scott Grosse 
What is MCADD? 
Medium chain acyl-CoA dehydrogenase deficiency (MCADD), a fatty acid 
oxidation disorder, is an autosomal recessive enzyme deficiency. This condition 
prevents the normal use of fat as an alternative source of energy during times of 
fasting or increased metabolic demands. People with MCADD cannot burn fat for 
energy when their bodies run out of glucose, and as a result they may be affected 
by low blood sugar, altered central nervous system function, coma, or sudden 
death.1, 2 If treatment is initiated before the onset of metabolic crisis, however, 
morbidity and mortality can be prevented.1 With an early diagnosis, MCADD can 
be managed successfully by eating regularly and avoiding fasting.2 
Why Test Newborns for MCADD? 
Plasma concentrations of MCADD markers in the blood decline significantly after 
the first few days of life.3 Because MCADD can be identified more easily during the 
newborn period, and pre-symptomatic treatment is reported to prevent morbidity 
and mortality, advocacy groups such as the March of Dimes2 have recommended 
universal newborn screening for MCADD. 
Tandem Mass Spectrometry Screening Test 
Tandem mass spectrometry (MS/MS) is currently used to screen for MCADD 
as well as for other metabolic diseases.4 This method detects elevated levels 
of certain intermediate metabolites of medium-chain fatty acids that are 
associated with MCADD. Octanoylcarnitine (C8) is the primary MCADD marker; 
additional markers include hexanoylcarnitine (C6), decanoylcarnitine (C10), and 
decenoylcarnitine (C10:1).3.5 
The high specificity and sensitivity of MS/MS to identify MCADD have been 
verified by reported results of newborn screening tests and retrospective MS/ 
MS analyses of specimens from individuals who have been diagnosed clinically. 
Combined results5-10 from 1.9 million newborn screening tests contained 
approximately equal numbers of true-positive (n=112) and false-positive (n=110) 
MS/MS test results and no known false-negative results. 
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Retrospective MS/MS analyses6,11-12 of 56 specimens from unscreened, clinically 
diagnosed MCADD patients produced only one false-negative result, obtained 
from a stored newborn screening blood spot sample that had been collected from 
a newborn in metabolic crisis. 
Adding MCADD Screening to Existing Newborn Screening Programs 
Professional groups, including the American Society of Human Genetics (ASHG) 
and American College of Medical Genetics (ACMG),13 have decided that the use 
of MS/MS in newborn screening programs might benefit patients. Many states14 
(Figure 1) have added screening for MCADD to their newborn screening programs 
and other states are currently considering adding screening for this disorder. 
The process by which states evaluate diseases as candidates for their screening 
programs varies. Massachusetts has documented the importance of an advisory 
committee in deciding to screen for MCADD.15 
Figure 1. State Newborn Screening Programs Performing MS/MS Testing for 
MCADD, as of January 200414 
Is Universal Screening for MCADD Justified? 
Reviews of MCADD as a candidate for newborn screening found that it fulfills either 
most16 or all17 of the criteria conventionally used to justify universal screening. 
MCADD is the most common fatty acid oxidation disorder. Newborn screening 
programs report prevalence between 1 in 12,500 and 1 in 25,000;5-10 this is similar 
to the frequency of phenylketonuria (PKU) in the same populations. 
The natural history of MCADD is still not well understood.18 It is unknown what 
proportion of people identified with MCADD through MS/MS screening would 
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become symptomatic without this screening and subsequent interventions. 
Identifying affected people who would otherwise remain asymptomatic could 
subject them to unnecessary medical therapies, psychological stress, and difficulty in 
obtaining health insurance. Population-based studies to demonstrate the usefulness 
of MCADD screening have been recommended.18 CDC and the Health Resources 
and Services Administration (HRSA) are funding follow-up studies of identified 
children to increase understanding of the impact of newborn screening for MCADD 
and other disorders identified by MS/MS. 
The potential impact of early identification and intervention for MCADD on 
mortality is not well understood. Estimated mortality among children clinically 
diagnosed with MCADD ranges from 8% to 25%.1,19-21 One study estimated 
mortality in an unscreened cohort of children with MCADD.4 This study found 
eight children with MCADD among 100,600 British children whose stored 
newborn blood spots were analyzed using MS/MS; one (12.5%) of the eight 
children with MCADD died. Larger studies of this type or prospective data from 
screening programs could provide more precise mortality estimates. 
The potential impact of newborn screening for MCADD on morbidity is unknown. 
Long-term neurological impairment has been reported in 16% to 33% of survivors 
of metabolic crises, about half of whom are seriously impaired.1,19-21 No cases 
of neurological impairment in children with MCADD identified by screening 
programs have been reported.22-24 Systematic long-term assessment of neurological 
outcomes is needed; although preliminary data from an assessment of infants 
born in New England and Pennsylvania indicate normal cognitive development.24 
Cost-Effectiveness of Newborn MCADD Screening 
The two published studies that analyzed cost-effectiveness of adding MS/MS to 
newborn screening concluded that it is probably cost-effective, either for MCADD 
alone9 or because of the added benefits from early detection of disorders in 
addition to MCADD.25 A study published in 2003 concluded that, for jurisdictions 
already using MS/MS to screen for PKU, it would be cost-effective to screen for 
MCADD as well.26 
The cost-effectiveness of screening (from the perspective of the screener) 
using MS/MS depends on the technology chosen and on assumptions about 
the numbers of lives saved and cases of disability prevented. According to the 
Wisconsin Public Health Laboratory,9 the laboratory cost of MS/MS screening for 
MCADD is about $4 per infant. The additional costs of confirmatory testing and 




Outcome of a treatment 
measured as the number of 
years of life saved, adjusted 
for quality. 
screened. The Wisconsin study estimated a cost-effectiveness ratio of $42,000 per 
quality-adjusted life years (QALYs) in the base-case analysis, and $6,000 in 
the best-estimates analysis. The authors concluded that the true cost-effectiveness 
ratio is probably below the normal cutoff of $50,000 per QALY most commonly 
used to justify healthcare interventions. 
Challenges for Implementing MCADD Screening 
The addition of new disorders to newborn screening programs presents many 
challenges. For MCADD, these may include implementing new technology in the 
laboratory and assuring appropriate follow-up to confirm the diagnosis of MCADD 
and begin effective interventions promptly. Legal and ethical issues are also 
present at every stage of developing and conducting newborn screening programs. 
Laboratory Implementation Issues: The use of MS/MS has proven to be a reliable 
method to screen for MCADD. Because plasma concentrations of MCADD markers 
decline significantly after the first few days of life,3 it is important to establish 
age-appropriate cutoff levels for newborn screening tests. CDC’s Newborn 
Screening Quality Assurance Program27 conducts proficiency testing surveys that 
have allowed U.S. newborn screening laboratories to meet Clinical Laboratory 
Improvement Amendments (CLIA) quality assurance (QA) requirements.28 The 
surveys include specimens enriched with three MCADD markers—C8, C6, and 
C10 (no synthetic standard is available for C10:1). 
Follow-Up Implementation Issues: Short- and long-term follow-up protocols 
are essential components of newborn screening programs.29 Several states have 
developed pilot short- and long-term follow-up studies. For example, Oregon and 
Iowa are part of a cooperative agreement with CDC to develop a long-term follow-
up protocol for MS/MS screening. 
Legal and Ethical Issues: MS/MS technology used for MCADD screening is able 
to detect more disorders than those mandated by newborn screening policy, 
although for many of these disorders, information about the clinical validity or 
utility of testing is not available. This presents an ethical dilemma that states 
have approached in various ways. In some states, parents are given the option to 
consent to receive results of non-mandated tests; other states do not make non-
mandated test results available. 
Conclusion 
Laboratory testing is only one element of an effective newborn screening program. 
Clinical follow-up is essential for optimizing outcomes for children and their 
families. Some states are conducting research that will help fill knowledge gaps 
related to MS/MS screening for MCADD and other disorders. For example, the 
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California Department of Health Services instituted a pilot program that lets 
parents volunteer to have their child undergo supplemental testing for MCADD 
and other disorders detectable by MS/MS technology. This project aims to 
generate epidemiological data that will be used to inform policy decisions about 
which disorders to add to the list of routine screening tests, as well as to evaluate 
protocols and develop guidelines for follow-up. 
Resources 
General 
National Newborn Screening and Genetics Resource Center (NNSGRC) 
1912 W. Anderson Lane, Ste. 210 
Austin, TX 78757 
Phone: (512) 454-6419 
http://genes-r-us.uthscsa.edu/index.htm 
March of Dimes (MOD) 
1275 Mamaroneck Avenue 
White Plains, NY 10605 
http://www.modimes.org/ 
Morbidity and Mortality Weekly Report (MMWR) 
April 13, 2001; Vol. 50; No. RR-3 
Using Tandem Mass Spectrometry for Metabolic Disease Screening Among 
Newborns: A Report of a Work Group 
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5003a1.htm 
Newborn Screening Quality Assurance 
In Genetics and Public Health in the 21st Century, Khoury MJ et al., editors.  
Oxford University Press, 2000. 
http://www.cdc.gov/genomics/info/books/21stcent3.htm 
Tandem Mass Spectrometry 
Newborn Screening Quality Assurance Program (NSQAP) 
http://www.cdc.gov/nceh/dls/newborn_screening.htm 
Policy/Legal Issues 
National Conference of State Legislators (NCSL) 
Denver Office: 
7700 East First Place 






Route 9-D / 21 Malcolm Gordon Road 
Garrison, NY 10524-5555 
Phone: (845) 424-4040 
Washington Office: 
444 North Capitol Street, N.W., Suite 515 
Washington, D.C. 20001 
Tel: 202-624-5400 
Fax: 202-737-1069 
For information re: genetics laws and legislative activity go to: 
http://www.ncsl.org/programs/health/screen.htm 
For information re: ethics and newborn screening project go to: 
http://www.thehastingscenter.org/research/prog2/healthcarepolicy_4.htm 
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Chapter 6
The Family History Public 
Health Initiative
increasing number of affected relatives, especially if their disease was diagnosed 
at an early age.1 Physicians usually collect information about a patient’s family 
2 
or children. Second-degree relatives include aunts, uncles, nieces, nephews, and 
i




than might be used for average risk individuals, 
• use of chemoprevention such as aspirin, and 
• referral to a specialist for assessment of genetic risk factors. 
Screening and prevention guidelines are available for many chronic disorders,3-6 
and data are accumulating regarding the effectiveness of these strategies for high-
risk individuals.7-9 
Paula Yoon and Maren Scheuner 
Family History Is Valuable for Prevention 
People who have close relatives with certain chronic diseases, like heart disease, 
diabetes, and cancer, are more likely to develop those diseases themselves. Studies 
suggest that having a first-degree relative with one of these diseases can at least 
double a person’s risk of developing disease; this risk generally increases with an 
history, but often do not discuss, revisit or update it over time. Thus, they may 
miss opportunities to offer specific prevention recommendations for diseases that 
run in the patient’s family. 
What is a First-Degree Relative? 
First-degree relatives include immediate blood relatives, such as parents, siblings, 
grandparents. First-degree relatives have approximately half their genes n common. 
From a genetic standpoint, you are closer to first-degree relatives because you 
Knowledge of increased risk for chronic diseases due to family history can 
influence the clinical management and prevention of a disease. Prevention 
targeted lifestyle changes such as diet, exercise, and stopping smoking, 




A trait that is determined 
by a single gene. 
Disease Risk Due to Gene-Environment Interactions 
Most common diseases result from the complex interactions of multiple genes 
with multiple environmental factors. These factors can include long-term 
exposures to pollution or sunlight, behaviors such as smoking or inactivity, and 
cultural factors such as diet. Despite progress in sequencing the human genome, 
considerable research is needed to understand the genes that predispose to 
chronic diseases. 
Among the genes that are being studied are genes that code for carcinogen 
metabolizing enzymes (e.g., NAT2 and GSTM1) and genes that regulate nutrient 
metabolism (e.g., MTHFR). Much work still needs to be done in order to 
understand how genes interact with each other and the environment to cause 
disease. In the meantime, family medical history represents a “genomic tool” that 
can capture the interactions of genetic susceptibility, shared environment, and 
common behaviors in relation to disease risk. 
Role of Genetic Testing 
Single-gene variants handed down in families may result in rare diseases such as 
Huntington’s disease. Some of these variants (e.g., of BRCA1 and APC) also result 
in common diseases, like breast and colorectal cancer. For more information, see 
Chapter 4, Public Health Assessment of BRCA1 and BRCA2 Testing for Breast and 
Ovarian Cancer. Fortunately, these variants are rare in the population, but when 
a harmful genetic variant is suspected in a high risk family, genetic testing may be 
possible. 
Confirming a suspected genetic risk can relieve anxiety related to not knowing and 
may suggest specific preventive interventions. Genetic testing can also reassure 
relatives when familial susceptibility can be ruled out. A genetic specialist can 
determine when genetic testing might be considered and can counsel the patient on 
the risks and benefits of the testing process. A family history assessment is the first 
step towards identifying high risk families who may benefit from a genetic work-up. 
Family History and the Family Tree 
Family history information that is needed to assess disease risk includes the 
number, gender, and closeness of affected relatives, their ages at disease onset, 
and any associated health conditions. Organizing this information into a detailed 
family tree or pedigree graphically illustrates clusters and inheritance of traits 
within families. Instructions for recording a family history and drawing a pedigree 




The CDC Family History Initiative 
The CDC Office of Genomics and Disease Prevention (OGDP) is collaborating 
with several CDC programs and the National Institutes of Health (NIH) in a family 
history public health initiative. The purpose of this initiative is to evaluate the 
use of family history for assessing risk for common diseases, as well as its role in 
influencing early detection and prevention strategies. 
The initiative began in early 2002 with a review of the existing literature and a 
paper that introduced the concept of using family history for disease prevention.1 
At a workshop in May 2002, experts reviewed family history as a risk factor for 
several chronic diseases including cardiovascular disease, diabetes, asthma, and 
several cancers. Workshop participants discussed the accuracy and reliability 
of family medical history and attempted to gauge how useful knowledge of 
family history might be for motivating people to change their behavior. A series of 
scientific papers based on the workshop presentations was published in February 
2003 as a theme issue in the American Journal of Preventive Medicine.10 
Interested workshop participants joined with others to form the Family History 
Workgroup in order to explore, develop and test family history tools for disease 
prevention. This multidisciplinary group includes representatives from CDC 
programs, the NIH, other federal agencies, state public health programs, academia, 
and the health care community. 
Selecting Diseases to Include in a Family History Tool 
The Family History Workgroup first established the following criteria for deciding 
which diseases should be included in a family history tool: 
• substantial public health burden, 
• clear case definition, 
• high awareness of disease status among relatives, 
• accurately reported by relatives, 
• family history is an established risk factor, 
• prevalence of family history can be estimated in the population, 
• effective interventions for primary and secondary prevention, and 
• different recommendations for groups at different levels of familial risk. 
The workgroup next reviewed other family history tools being used or developed 
for primary care and compiled a list of approximately 45 diseases that were 
included in these tools. After applying the inclusion criteria, the workgroup 
narrowed the list to 15 diseases. 
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Prototype Family History Tool 
For public health purposes, family history tools should be simple, easily applied, 
and adaptable to different settings. Most of the existing family history tools that 
the workgroup reviewed were found to be too lengthy and difficult to interpret. 
The workgroup decided in May 2003 to develop a prototype family history tool 
that would include only a few diseases, making it easier to pilot test and evaluate 
in population-based settings. The diseases included in the prototype include: 
•	 heart disease, 
•	 stroke, 
•	 diabetes, and 
•	 colorectal, breast and ovarian cancer. 
The prototype family history tool consists of a three-step process of data 
collection, risk classification, and recommendations for intervention, as shown in 
Figure 1. 
Data Collection 
The family history tool prototype is called Family Healthware. It is computer-based 
and self-administered and can be completed in a provider’s office or at home 
before a medical consultation. The work group decided to create an electronic 
version of the tool that can process complex familial risk algorithms and provide 
feedback to patients and physicians. When completed, the tool will be made 
available as a CD-ROM and as a download from the Internet. Other formats, such 
as paper-based or touch-screen versions, are also being considered. 
Family Healthware will collect: 
•	 personal information, including age, gender, and race/ethnicity, 
•	 numbers of relatives in each category (mother, father, children, siblings, 
grandparents, aunts, and uncles), 
•	 personal history of heart disease, diabetes, stroke, colorectal cancer, breast 
cancer, and ovarian cancer, indicating whether age at diagnosis was below 
or above a disease-specific age threshold (e.g., age 60 for heart disease), 
•	 history of the same six diseases for relatives and age at diagnosis in each 
category, and 
•	 personal risk factors, such as body mass index (determined by height and 
weight), diet, exercise, use of tobacco products and alcohol, and screening 
behaviors such as mammogram and cholesterol screening. 
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Classification 
Family Healthware will include software algorithms that interpret the data and 
provide a brief synopsis of disease risk and suggestions for follow-up. The goal 
is to keep data collection simple while gathering enough information to classify 
people into risk levels. The underlying scheme being considered includes three 
risk levels—average, above average, and much above average—that are determined 
mainly by the number and closeness of affected relatives and their ages at disease 
onset.11 The risk classification would be used to guide and inform prevention 
activities. 
Figure 1, Example: Proposed scheme for using family history to guide 





















Familial Risk Classification: 
Intervention 
Family Healthware is being developed for use in primary care settings and for 
public health purposes. Primary care providers can play a major role in prevention 
by reviewing their patients’ family histories and making recommendations for early 
detection or intervention strategies and counseling on lifestyle. Patients will be 
able to maintain and update their family history records at home and can discuss 
the implications with their providers during annual visits. The general public will 
also be able to retrieve the tool from the Internet and complete the assessment at home. 
Family Healthware will produce an individualized assessment page that indicates 
the level of familial risk for each disease, and may include prevention messages 
about recommended behavior changes and screening. 
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lso available at: 
An electronic resource manual that complements the tool is being developed 
for health care providers. The resource manual is organized into disease-specific 
chapters and includes an explanation of risk levels, including possible genetic 
conditions underlying “much above average” risk, and suggestions for assessment 
of additional risk factors. The resource manual will also include recommended 
preventive interventions for each level of risk (if available), and additional 
resources for health care providers and patients. These recommendations will 
be evidence-based, appropriately referenced, and supported by links to other 
Web sites, such the National Cancer Institute, the American Cancer Society, the 
National Heart, Lung and Blood Institute, the American Heart Association, Online 
Mendelian Inheritance in Man, and GeneClinics/GeneTests. 
Evaluation Studies 
Extensive pilot testing and evaluation studies are being planned to examine the 
validity and utility of the Family Healthware prototype. At the end of FY 2003, 
CDC awarded funding to three research centers—the University of Michigan 
School of Medicine, Evanston Northwestern Healthcare Research Institute, and 
Case Western Reserve University School of Medicine—for a collaborative study 
set in primary care clinics. The study will assess whether family history risk 
assessment, classification, and personalized prevention messages influence health 
behaviors and the use of preventive medical services. Additional studies will be 
developed to evaluate the tool in other public health and preventive medicine 
settings. 
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Genetic Testing and the 
Prevention of Coronary Heart 
Disease: A Case Study




called the health department because he was looking for an objective opinion, 
unbiased by provider preferences or commercial interests. 
Diseases of the heart are the leading cause of death in the United States, 
accounting for almost one third of all deaths. Most of these are due to CHD, 
declining substantially during the 20th
detection and intervention.1 
th
Concurrent detection of 
multiple gene variants 
that have been associated 
with predisposition to a 
particular disease. 
A 50 year-old man, Mr. C, calls the Department of Public Health with a 
“Will a  test help me know what I should do to prevent coronary 
Mr. C says that his father had a heart attack when he was 59 years old. He 
knows that he needs to take care of his health and just had a complete physical, 
including an electrocardiogram and a treadmill test. Everything checked out 
fine, but because his cholesterol was “a little high,” his doctor recommended 
a reduced-fat diet and prescribed a lipid-lowering drug. Mr. C’s wife then 
asked her doctor, an alternative medicine practitioner, for another opinion. 
He suggested that Mr. C should look into the new DNA tests that provide 
an individualized “genomic profile” and personalized recommendations for 
nutritional supplements to prevent coronary heart disease. Mr. C visited several 
Web sites that offer such tests, but wasn’t sure whether he should get one. He 
Is Genomic Profiling for Coronary Heart Disease (CHD) Ready for Prime 
Time? 
including deaths from myocardial infarction and CHD-related heart failure. After 
 century, CHD and stroke incidence and 
mortality may be leveling off, suggesting the need not only for redoubled efforts 
but also for modified strategies to promote healthy lifestyles and improve early 
Mr. C turned 50 in 2003, the year that also marked the 50  anniversary of the 
discovery of DNA and completion of the Human Genome Project. Sequencing 
the genome ahead of schedule has further heightened expectations that health 




people individualized estimates of risk and interventions based on their genotypes 
has captured the imagination of scientists and the public. This enthusiasm for 
personalized medicine has fueled a rush to develop and market new genomic 
tests, often without establishing that the tests are valid or useful. 
Several commercial enterprises have sprung up to offer DNA-based tests for 
susceptibility to complex diseases, with names such as Obesity Susceptibility 
Profile, Nutritionscreen, Oxidative Stress Profile and CardioGenomic Profile.* 
These tests are advertised on Web sites that offer extensive information targeted 
to consumers, as well as information for health care providers. These “genomic 
profiles” typically consist of tests for combinations of gene variants; the specific 
combinations are considered proprietary and are usually not disclosed in online or 
printed product information. 
A critical evaluation of genomic profiling for guiding individualized health 
promotion and disease prevention concluded that this approach is “not ready for 
prime time” because of lack of evidence in two key areas: 2 
1.	 Clinical Validity: Many initial reports associating one or more genetic 
variants with coronary heart disease are not confirmed—and are 
sometimes contradicted—by subsequent research studies. Systematic 
approaches to reviewing the evidence are still in early stages of 
development. 
2.	 Clinical Utility: Does genomic profiling provide any information that 
would change individual prevention or management recommendations? 
Do these recommendations result in positive behavior change and reduced 
morbidity and mortality? 
Medical Family History as Genomic Profiling 
An established approach to “genomic profiling” that should not be overlooked 
is the medical family history. The tendency for coronary heart disease (CHD) to 
cluster in families was first recognized over one hundred years ago. A positive 
family history can capture the effects and interactions of shared genetic and 
environmental factors, whether measured or unmeasured, that lead to disease 
expression in a family: “it is quite possible that even with our ability to measure 
hundreds and thousands of genes and environments we may find that family history is 
the best, low-cost way to identify the at-risk subgroups in the population.” 3 In this respect, 
family history is as relevant to public health programs as it is to clinical practice.4, 5 
*Use of trade names is for example only and does not imply endorsement of DHHS. 
For examples, see Genovations: Predictive Genomics for Personalized Medicine, http:// 
www.genovations.com; Sciona, http://www.sciona.com; GeneLink: Genetic Biosciences for 
Improving the Quality of Life, http://www.bankdna.com. 
48 
Family History is Still the Best Genomic Tool 
In 2002, a meeting on genomics and chronic disease, conducted by the Chronic 
Disease Directors, a national organization affiliated with the Association of State 
and Territorial Health Officials, called for investigating the utility of targeting 
interventions to persons at risk for chronic diseases because of their family 
history.6 The meeting report called for extending the use of family history beyond 
high-risk families to the much larger group of families at moderate risk for chronic 
disease due to shared genetic background and environment. This interest spurred 
the development of the Family History Initiative. See Chapter 6, The Family History 
Public Health Initiative, for more information. 
Guidelines for CHD Prevention 
Public health agencies and medical care systems are promoting the use of 
evidence-based guidelines that incorporate family history information to manage 
risk factors and treat heart disease. The following reports provide examples: 
The Seventh Report of the Joint National Committee on Prevention, 
. 
American Heart Association Guidelines for Primary Prevention of 
The guide calls for identifying high-risk patients for whom screening and 
http://circ.ahajournals.org/cgi/content/full/106/3/388 
Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) 
Family history of premature cardiovascular disease (men under age 55 or women 
under age 65) is identified as a major risk factor for CVD. 
http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm 
The Third Report of the Expert Panel on Detection, Evaluation, and Treatment 
of High Blood Cholesterol in Adults (Adult Treatment Panel III) 
Family history should serve as a factor for making treatment decisions relative to 
setting and reaching LDL-cholesterol goals. 
http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm
Cardiovascular Disease and Stroke: 2002 Update 
intervention in first-degree relatives (including children) would be an important 
aspect of primary prevention. 
Conclusion 
Mr. C already knows that because of his father’s history, he needs to focus on actions 
to reduce his risk of CHD. Taking a more detailed family history of CHD and stroke 
could help Mr. C and his doctor discuss additional ways to reduce his risk. Mr. C didn’t 
mention whether his father is the only relative with CHD or discuss his cholesterol level, 
except to say it was “a little high.” Although inherited high-risk syndromes like familial 
hypercholesterolemia account for only a small proportion of CHD, failure to detect them 
49 
http://www.chronicdisease.org/Genomics_Summit_Report.pd . Accessed Feb 16, 2004.
can have serious consequences for affected individuals and families.7 A documented 
medical family history is valuable for distinguishing both moderate- and high-risk 
individuals and families. 
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Genomics and Public Health: 
Ethical, Legal, and 
Social Issues
Toby Citrin and Stephen M. Modell 
Introduction 
This article is divided into sections discussing key ethical, legal and social 
implications of genomic science for public health. It includes resources that 
may help public health professionals develop an approach for resolving these 
issues as they take shape now and in the future. Ethical, legal and social are 
somewhat arbitrary categories because these issues are almost always intertwined. 
For example, the potential misuse of genetic information for purposes of 
discrimination and stigmatization raises ethical concerns, points out the need for 
protective legislation, and describes a significant social problem. Ethical, legal 
and social issues may be either real or only perceived, but the distinction between 
reality and perception often does not matter to consumers and policy makers. 
Examining these issues from a public health perspective can be helpful in either 
instance. 
Ethical, Legal and Social Issues (ELSI) 
During the last decade and a half, the National Human Genome Research Institute 
(NHGRI) has supported an extensive program of scholarly work on the ethical, 
legal, and social implications of genetics research, known collectively as ELSI. ELSI 
inquiry examines the values underlying the use of new genetic technology, ideally 
before it is in use. 
Public Health Ethical, Legal and Social Issues (PHELSI) 
Since 1999, genetic research has increasingly focused on the discovery of human 
genetic variations linked to susceptibility to common illnesses, rather than on 
the rare, single-gene disorders that have been the traditional focus of clinical 
genetics. Efforts to understand and prevent these more widespread conditions, 
which often involve complex gene-environment interactions, fall under the 
purview of public health. We have used the term PHELSI to refer to ethical, legal 
and social implications that arise when genomics is used for the advancement of 
public health. 
Single-Gene Disorder 
Refers to a disorder that 
is determined by a single 
gene. 
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Is PHELSI Different From ELSI? 
The ethical, legal and social implications of using genetic technology in medicine 
have been the subject of a rich and growing literature.1 Most of this scholarship 
has applied principles of bioethics to the use of genetics in medical research and 
practice, and emphasizes the individual and the patient-physician relationship. 
At the same time, there has been a renaissance in the literature on public health 
ethics in the past decade. Public health actions are intended for the public good, 
defined either in terms of groups of individuals or the population as a whole. 2 
The public health perspective is at the center of the distinction between PHELSI 
and ELSI. 
Public Health Ethics 
While scholars have considered the ethical principles underlying public health 
practices for many years, more recent scholarship has made a distinction between 
bioethics and principles more specifically relevant for public health. Lachmann 
writes about the “conflicts between the priorities of public health and the 
emphasis of medical ethics on the duty of the doctor to the individual patient”.3 
Lane et al. describe the historical identification of bioethics with the rights of the 
individual, limiting its value to address current issues of public health—especially 
issues relating to health disparities among different demographic groups.4 
Rothstein has identified an “ongoing need to reassess [public health’s] scientific, 
ethical, legal, and social underpinnings”,5 and Cole has pointed out that most 
public health programs require an explicit fundamental justification which can 
be based upon principles of morality.6 Other scholars have recently formulated 
frameworks for the application of ethics in public health,7,8 and have identified 
literature uniquely appropriate for considering ethical issues in public health.9 
The American Public Health Association has promulgated a Public Health Code 
of Ethics.10 
As genomics is increasingly studied and practiced in the public health context, 
it is useful to analyze the ensuing ethical, legal and social issues using a public 
health framework that emphasizes: 
•	 the use of science to further the health of the population, rather than the 
health of particular individuals, 
•	 the welfare of the collective as well as the autonomy of the individual, 
•	 issues of discrimination and health disparities, 
•	 the historical relationship between public health and distributive justice 
(the societal obligation to be fair when providing health resources to 
different groups), and 
•	 balancing the prevention of disease against the curing of illness.11 
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Scrutiny of the Tuskegee syphilis study and the discriminatory sickle cell screening 
programs of the 1970s has led public health officials to emphasize the avoidance 
of social harms to particular groups (e.g., African Americans); in addition to the 
desire to avoid harm, public health ethics are also concerned about treating all 
groups with fairness. The principle of social justice seen through the lens of public 
health ethics requires that differences in race/ethnicity, socioeconomic status, 
and inherited family background should not skew how the benefits of genomic 
research are distributed.4,12 Public health policy offers a variety of safeguards 
against potential inequities, from public education to collective action. 
Ethical Issues in Public Health Genomics 
As genomic research points out new ways to identify persons at risk, using this 
knowledge presents new ethical challenges. Most of the literature on ethical 
issues related to public health genetic screening deals with mandatory newborn 
screening programs for single-gene disorders (e.g., phenylketonuria and sickle cell 
disease). Tests for these disorders have high predictive value, and treatment can 
either eliminate or reduce the severity of symptoms. Tandem mass spectrometry, 
in contrast, has delivered an expanded list of potential newborn screening tests, 
for which predictive value and usefulness are less certain.13 See Chapter 5, Newborn 
Screening for MCAD Deficiency, for more information. 
Increasingly, screening programs are being suggested for the identification of 
individuals at risk for chronic disease (e.g., cystic fibrosis, hemochromatosis, 
coronary heart disease, and cancer), suggesting a different balance of ethical 
considerations.14 An even more divisive ethical area is prenatal screening for 
conditions without definitive or effective treatment, e.g., beta-thalassemia 
(Cooley’s anemia), Tay-Sachs disease, or serious or fatal trisomies. Some 
have argued that the focus of public health efforts should be on “phenotypic 
prevention” (the prevention of disease manifestation) rather than “genotypic 
prevention” (avoiding the birth of individuals with a given genotype).15 Others 
have pointed out the benefits of prenatal screening as a public health intervention, 
given that it provides couples with risk-related information. The informed couple 
can use this information in their decision-making, and make specialized plans in 
the case of a decision to deliver an infant with a genetic condition.16 
The use of family history to identify individuals at risk for disease has been a 
traditional tool of medical diagnosis and is now being tested as a potentially useful 
public health tool for identifying at-risk populations.17 See Chapter 6, The Family 
History Public Health Initiative, for more information. Similarly, information on 
averted deaths (e.g., from arrhythmia in long QT syndrome) and on cause of death 
from death records has been proposed as a basis for identifying family members at 
risk for the same disease.18 The use of family history and death records, however, 
raises the issue of privacy rights of persons alive or dead.19 
Trisomy 
The presence of an extra 
chromosome, resulting in 
a total of three 
chromosomes of that 
particular type instead 
of the usual pair. 
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Another area of increasing public health interest is the use of existing biological 
samples gathered for one purpose, e.g., blood spots from newborn screening 
programs, or blood collected for the National Health and Nutrition Examination 
Survey (NHANES), (see Chapter 1, National Health and Nutrition Examination 
Survey), for other applications, such as epidemiologic research and identifying 
individuals with similar risk profiles who could benefit from screening.20, 21 
Each of these current and potential public health activities raises issues of 
informed consent, confidentiality of genetic information, potential stigmatization 
and discrimination, and the balancing of individual autonomy against the public 
health goal of collective action. Appropriate analysis of these issues requires care 
in order to maintain a clear distinction between activities undertaken for research 
and those to be implemented in public health practice.22, 23 
Legal Issues in Public Health Genomics 
Each of the ethical issues identified above can also be considered from a legal 
perspective. In general, laws and policies to guide the use of genomic technology 
lag far behind its actual application in medical and public health practice. While 
legal scholars have developed useful models of legislation, summaries of relevant 
state legislation maintained by the National Conference of State Legislatures 
disclose diverse policies, variable responses among states to the need for 
legislation, and lack of consensus on whether federal, state or mixed legislation is 
most appropriate.24 Variance also exists within and among states in the spread of 
protections offered by state public health records privacy laws, further complicated 
ct HIPAA) privacy rules on 
unauthorized disclosures of health information.25 
A growing area of concern is commercialization arising from the private ownership 
of genomic technology, and the increasing conflict between financial incentives 
driving the marketing of biomedical technology and the public health goal of 
maximizing the public’s health through cost-effective interventions.26, 27 
Social Issues in Public Health Genomics 
The incorporation of genomics in public health practice has significant 
implications for social policy. As we consider the implications of each new 
genomic intervention in public health, it is essential that we also consider the 
cumulative impact of genomics on the nature of our society. Two related areas of 
social concern are fears of a rebirth of eugenics and the potential of genetics to 
widen health disparities between different demographic groups. 
Historians have pointed out the intersections between public health and eugenics 
during the early 20th century and the danger that new genetic technologies might 
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be misused to serve goals other than that of preventing disease. Pernick warns that 
“Past similarities between eugenics and public health serve as an alarm clock for 
all the health sciences, not as a lullaby for genetics”,28 and Duster has expressed 
concern that given the discriminatory context of American society, the application 
of new genetic technologies could lead to a return of eugenics through the “back 
door”.29 Conversely, Kitcher has described the positive potential of “utopian 
genetics” to serve public health goals, given adequate public education and equal 
access to genetic technology.30 
The “double-edged sword” of genetics pointed out by many commentators can 
result in either the widening or the narrowing of health disparities among the 
population. An increasing amount of genetics research is focused on chronic 
diseases, and highlights group disparities in disease frequency. Disparities in 
access to the benefits of genomic research, or the distortion of research findings 
to stigmatize racial and ethnic minorities, could further widen health inequities.31 
If the new tools of genetics are made available to all who could benefit, however, 
the prevalence of many chronic diseases could be reduced in the American 
population. 
Engagement and Education to Address PHELSI 
How can we realize the positive potential of genomics as a tool of public health 
while avoiding social harms? The literature suggests that the related strategies of 
public engagement and public education are crucial. 
The active engagement of an informed public is essential to ensuring that 
these new, powerful scientific tools are used in the public interest to achieve 
improvements in total population health. A large and growing body of literature 
has developed to define and support a resurgence of civic participation in policy 
making.32, 33 The NIH-funded project Communities of Color and Genetics Policy has 
demonstrated a successful process for engaging minorities in policy development 
to address concerns of special relevance to African-American and Latino citizens.34 
In addition to participation in community policy making, the representation of 
diverse groups on newborn and chronic disease advisory committees and among 
key genetics decision-makers should be a major priority of public health. 
The most important factor for determining whether genetics will enhance or 
impede public health goals is the extent to which the public is adequately 
informed about genetics. Unfortunately, a large share of public knowledge about 
genetics has been derived from mass media, highlighting presumed genetic 
breakthroughs, and fostering a sense of genetic determinism. The interplay of 
genes and environment in most diseases is not widely understood.35 
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Public health leadership should promote citizen education in several 
ways: 
• Information to the Media: 
Public health professionals in practice and academia should become 
providers of accurate information on genetics to the media, in order to 
counterbalance the more sensational reporting that too often occurs. The 
public health viewpoint can add depth and social concern to the sources 
often tapped by the media for information: biomedical researchers and 
corporate biotech and pharmaceutical firms. 
• Education: 
Public health practitioners have a role in responding to teaching requests 
from social and civic organizations, and in providing “information-on-
demand” resources relating to genetics.36, 37 In addition, academically-based 
public health professionals have the responsibility of assuring that future 
public health practitioners are knowledgeable about public health genetics 
and PHELSI issues.7, 38 A fundamental, long-term educational strategy 
also includes K-12 education. Since most formal education in genetics is 
acquired by the end of high school, it is essential that this basic education 
be accurate and stress the ethical, legal and social implications of genetics 
as well as the science.39 If our youth learn about genetics as one of several 
factors influencing health and disease, and as a growing technology that 
can be put to beneficial or harmful uses, they will have the intellectual 
background to interpret and judge other sources of information on genetics 
that they encounter as adults. 
A Genetic Agenda for Public Health 
Our brief review of the literature on PHELSI suggests several key roles for public 
health professionals in public health agencies, academic institutions, or other 
organizations whose work involves improving community health. In addition to 
learning about and using genetic tools that can be incorporated in public health 
practice, public health professionals must address the ethical, legal and social 
issues that arise. They can carry out this role in their practice and by encouraging 
public engagement, promoting public education, and becoming effective providers 
of balanced information. By assuming these responsibilities, public health 
professionals will help assure that genetic technologies are applied in ways that 
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Carrier Testing for Cystic Fibrosis:
Transition from Research to 
Clinical Practice
Autosomal Recessive 
Inheritance of two copies 
of a mutant gene, one from 
each parent, on one of the 
22 autosomes (chromosomes 
other than X or Y). 
Linda A. Bradley and Ira Lubin 
About Cystic Fibrosis 
Cystic fibrosis (CF) is one of the most common autosomal recessive genetic 
diseases in North America, occurring most frequently in Caucasian Americans 
of European descent, and less frequently in other racial and ethnic groups, such 
as African Americans and Asian Americans. CF is characterized by chronic lung 
disease, problems with digestion, and male infertility. Pancreatic problems occur 
in 85% of affected individuals, but lung function is the critical factor in prognosis 
and survival. 
CFTR: The CF Gene 
The CFTR gene was identified on Chromosome 7 in 1989, and controls the 
production of cystic fibrosis transmembrane conductance regulator (CFTR) protein. 
This protein controls the flow of salt and water in and out of cells, particularly 
those that line the lungs and digestive system. Abnormal CFTR protein results 
in reduced flow of water and build-up of thick secretions, and leads to the 
characteristic symptoms of CF. 
Over 1,000 disease-associated changes, or mutations, have been identified in the 
CFTR gene, but most are rare. One mutation, ∆F508, is by far the most commonly 
found among Caucasians of European descent. In this group, about 1 in 25 
persons is a carrier —that is, has one CFTR gene with a mutation and one normal 
CFTR gene. Carriers are asymptomatic and not at risk for CF.  Individuals with CF 
have mutations in both CFTR genes—one from each parent—and are deficient in 
functional CFTR protein. 
Cystic Fibrosis Carrier Testing 
Following the release of a practice guideline on prenatal/preconception cystic 
fibrosis carrier testing in October of 2001, the number of pregnant women 
choosing to have this testing is increasing rapidly. One laboratory reported an 
increase from 1,000 tests per month in 2001 to 14,000 tests per month in mid-
2003.1 It is possible that as many as a million women (about 25% of all U.S. 
births) could be opting for testing within the next year. Understanding the history, 
successes and problems of this first population-based testing effort can provide 
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vital information about what is needed for a successful transition of a genetic test 
from research to clinical and public health practice in the United States. 
History of CF Testing in the United States: 
Transition from Research to Clinical Practice 
When the CFTR gene was discovered in 1989, widespread testing for CF mutations 
became a possibility. Experts cautioned, however, that screening in the general 
population should await improvement in the sensitivity of the test as well as the 
results of pilot testing.2 In 1997, an NIH Consensus Conference reviewed existing 
knowledge about CF and the results of CF carrier testing pilot studies.3 The 
Consensus Panel recommended that CF carrier testing should be offered to: 
•	 couples seeking prenatal care or planning a pregnancy, 
•	 adults with a family history of CF, and 
•	 partners of persons with CF. 
The Consensus Panel also emphasized that this testing should be phased in, to allow 
time for development of laboratory resources and educational materials for patients 
and their health care providers. 
Subsequent workshops considered issues related to implementation of CF testing in 
routine practice.4,5 A joint committee of the American College of Medical Genetics 
(ACMG), the American College of Obstetricians and Gynecologists (ACOG), and the 
National Human Genome Research Institute (NHGRI) was designated to coordinate 
the development of guidelines for provider and patient education, informed consent, 
and laboratory testing and reporting. 
In spite of concerns about appropriate use and performance of CF testing, 
some consensus emerged in the following years. By 2001, some geneticists 
and obstetricians had begun offering this testing option to selected groups.6,7 
Widespread introduction of screening really began, however, when the ACMG 
published Laboratory Standards and Guidelines for Population-Based Cystic Fibrosis 
Carrier Screening8 and ACOG distributed to its membership Preconception and 
Prenatal Carrier Screening for Cystic Fibrosis: Clinical and Laboratory Guidelines (see 
Resources). 
The joint ACOG/ACMG guidelines recommend that CF testing should be: 
•	 offered to people with a family history of CF and to reproductive partners of 
persons with CF, 
•	 offered to couples where one or both partners are Caucasian and are 

planning a pregnancy or seeking prenatal care, and
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•	 available with appropriate information about limitations to couples in other 
racial or ethnic groups who are at lower risk and for whom testing is less 
effective (e.g., Hispanics, African Americans, Asian Americans). 
These and more recent9 guidelines are intended to assist health care providers and 
laboratories in implementing clinical recommendations. They describe laboratory 
standards, ways to convey expectations and limitations of testing, and prenatal 
diagnosis options for identified carrier couples. 
• CF occurs in about 1 in 2,500 Caucasian newborns of European descent. 
• testing occur at a rate similar to other clinical 
10 
• About 88% of 
by testing for 25 common mutations. In this high-risk group, about 78% of 
11 
• 
mutations in other U.S. populations: 
Carriers Carrier couples* 
Hispanic Caucasian  52 27 
42 18 
Asian American  24  6 
*Estimates assume that both members of the couple are from the same racial/ 
mutation. 
Key Facts About CF Carrier Testing 
Laboratory errors in CFTR 
laboratory tests (U.S. estimate is about 1-2% of test results). Performance 
may improve with experience and the use of confirmatory testing.
CFTR mutations in non-Hispanic Caucasians can be identified 
carrier couples can potentially be identified.
The 25-mutation testing panel identifies a smaller proportion of CFTR 
Population Identified using 25 mutation testing panel (%)
African American
ethnic group, and that both members carry a CFTR
Evaluation of Prenatal CF Screening 
To support the transition of molecular technology from research to use in 
clinical and public health practice, CDC funded a model process to evaluate 
genetic tests by assembling, analyzing, and reporting available data on safety and 
effectiveness. The report, Population-Based Prenatal Screening for Cystic Fibrosis 
via Carrier Testing, summarizes what we currently know about using the CFTR 
test for prenatal/preconception carrier testing, and was written for health care 
professionals, payers, and policy makers (http://www.cdc.gov/genomics/activities/ 
FBR/CF/CFIntro.htm). 
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2003: Learning from Implementation and Practice 
In 2003, a large U.S. genetic testing laboratory and the ACMG focused scientific 
and media attention on potential problems related to CF carrier testing.12 For 
example, it was reported that as many as 20 couples may have had prenatal 
diagnostic testing (i.e., amniocentesis) that was “unnecessary” based on current 
guidelines—that is, the couples’ risk of having a child with CF was not high 
enough to warrant a recommendation that those couples consider prenatal 
diagnosis.13-16 
There was widespread debate about whether such a problem is more likely to 
result from (a) misinterpretation of complex testing results by providers, (b) 
variability in laboratory compliance with existing clinical guidelines, (c) poor 
communication between laboratories and providers, or (d) clarity and content 
of reports of DNA test results.14-16 It should be noted, however, that the extent 
of this, and other anecdotally-reported implementation issues, remains unclear. 
Among the tens of thousands of women screened, it is not known what problems 
are being encountered, nor how frequently. Very little reliable data are currently 
available on the numbers and characteristics of women using this testing, and 
even less on outcomes of testing. 
Public Health Importance of Lessons Learned
 In response to these concerns, the CDC and Mt. Sinai School of Medicine hosted 
a conference on Communication: Key to Appropriate Genetic Test Referral, Result 
Reporting and Interpretation that focused on CF carrier testing as a model, and the 
Genetics and Public Policy Center at Johns Hopkins University convened a panel 
discussion on the use and regulation of CF testing.17 These events provided an 
opportunity for interaction between clinicians, laboratory professionals, policy 
makers, payers, the public health community, and consumers. Some topics 
included: 
Challenges in educating health care providers and consumers: 
•	 Informed health care providers, consumers, payers, policy makers, and 
others are crucial for ensuring that integration of genetic tests into routine 
care yields the greatest benefit and results in minimal harm. 
•	 Validated educational materials about genetic tests for health care providers 
and consumers need to be readily available and usable, in order to ensure 
that both the provider and the patient understand the benefits and 
limitations of testing. 
•	 In order to ensure appropriate use of new tests and facilitate smooth 
integration into routine practice, best practice guidelines must be 
widely disseminated to laboratories and health care providers, including 
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specialists and general practice physicians, mid-level practitioners (e.g., 
midwives, physician assistants, nurse practitioners), nurses and health 
educators. 
Communication between health care providers and laboratories: 
•	 Testing involves many steps: selecting the appropriate genetic test, the 
process of information and consent, obtaining and forwarding the correct 
specimen and patient information to a qualified laboratory, performing and 
reporting the test, and communicating results both to the provider and to 
the patient. 
•	 Laboratories report difficulty in obtaining key patient information (e.g., 
reason for testing, family history, race/ethnicity) that is needed to select the 
appropriate test, and to interpret results correctly. 
•	 Health care providers report variability among laboratories in test ordering 
and reporting practices and in how patient information is collected and 
used. They describe a need for test requisitions and reports that are simple 
and clear, and that use standardized terminology. 
Compatibility of clinical and laboratory guidance with U.S. healthcare delivery 
models: 
•	 Physician offices and clinics may lack resources to support some aspects of 
CF testing, such as educating patients, documenting consent, and providing 
access to key resources and expertise (e.g., genetic counseling, diagnostic 
testing) when appropriate. 
•	 Key patient information must be collected and transmitted to the laboratory; 
this process may become complicated when, for example, patients leave the 
doctor’s office to have blood drawn. 
•	 Preconception/prenatal CF carrier testing has provided insight into other 
potential complications related to our health care delivery system. For 
example, offering testing is recommended for partners of women who 
have been identified as CF carriers. The partner’s sample may be sent to 
a different laboratory, however, because a different physician has ordered 
the test or because the partner has different insurance coverage. This raises 
questions about appropriate linkage and interpretation of the couple’s test 
results, as well as the potential difficulty of monitoring the effectiveness 
of CF carrier testing in practice —questions that can only be answered by 
testing surveillance and data collection.     
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Post-implementation data collection to assess the public health impact of 
testing: 
The number of CF carrier tests performed is increasing rapidly, but good data on 
utilization, quality, acceptability, and access are lacking. Problems encountered 
in the transition from research to clinical practice need to be documented and 
quantified, and the data used to reevaluate the screening process and make timely 
changes in recommendations and guidelines as needed. 
•	 Population-based data on prevalence of genetic variants in affected and 
healthy populations are needed to select mutations to be included in 
genetic testing panels, and to re-evaluate such panels as new data become 
available. The 25-mutation CF panel is currently under review. 
•	 Test request and reporting formats should facilitate communication 
between clinicians and laboratories and support proper interpretation of 
genetic tests. 
•	 U.S. healthcare delivery models that link the patient to medical 
professionals, laboratory testing, counseling services, and payment options 
should be examined to assure appropriate services are accessible and cost 
effective. 
•	 When a genetic test makes the transition from research to practice, 
appropriate data collection must continue to monitor its quality, 
acceptability, accessibility, utilization, usefulness, and fit with healthcare 
delivery models. 
In recognition of the significance of the issues raised, additional CDC initiatives 
are being developed, including efforts to support effective pre-implementation 
evaluation of tests, facilitate partnerships between laboratories and health care 
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Ensuring the Quality of 
Genetic Testing in the 
United States 
Bin Chen and Linda A. Bradley 
Why is the Quality of Genetic Testing Important to Public Health? 
Genetic tests for about 1,000 health conditions have been developed, of which more 
than 600 are currently available for clinical testing.1 Many genetic tests identify DNA 
variants; others measure biochemical markers or analyze chromosomes. Most are 
used for diagnosis of rare single-gene disorders or chromosome abnormalities, and a 
few are used for newborn screening.2 
A growing number of genetic tests may have population-based applications, 
including determining the risk of developing a disease or condition in the future 
(e.g., predictive testing for breast cancer or cardiovascular disease), and recognizing 
genetic variations that can influence response to medicines (pharmacogenomics). 
These genetic tests, therefore, have the potential for broad public health impact. 
About GeneClinics and GeneTests 
The GeneClinics and GeneTests Web site, a publicly funded medical genetics 
information resource, contains comprehensive reviews of common genetic 
disorders and information on available genetic tests. Either of these links will 
take you to the Web site: g or http://www.genetests.org. 
Genetic Testing Issues 
Important issues that have been raised regarding genetic testing include the need 
to: 
• facilitate translation of research findings to quality testing in clinical and 
public health settings, 
• prevent premature commercialization of tests before safety, efficacy, and cost-
effectiveness can be established, 
• provide information on proper use of genetic tests to health care providers, 
policy makers, and the public, 
Pharmacogenomics 
Refers to the use of genomic 
techniques to enhance drug 




•	 maintain adequate oversight of genetic testing, 
•	 monitor the use of genetic tests and ensure appropriate access to testing 
and related clinical services, and 
•	 address complex social issues posed by genetic testing. 
Who Considers These Issues in the United States? 
In 1997, the National Institute of Health (NIH)—Department of Energy (DOE) 
Task Force on Genetic Testing issued a report on genetic testing in the United 
States that provided recommendations on how to ensure the development of 
safe and effective genetic tests.3 In 1998, the Department of Health and Human 
Services (HHS) established the Secretary’s Advisory Committee on Genetic 
Testing (SACGT) to provide advice on medical, scientific, ethical, legal, and 
social issues raised by the use of genetic tests. In consultation with the public, 
SACGT considered potential mechanisms and options for evaluating genetic tests, 
providing information about genetic testing to stakeholders, and enhancing testing 
oversight.4 
In 2003, HHS established the Secretary’s Advisory Committee on Genetics, Health 
and Society (SACGHS), in order to address genetic issues in a broader scope and 
continue discussion on oversight of genetic testing. Other public and private 
entities that consider issues related to the safety and effectiveness of genetic tests 
include: 
•	 federal and state government agencies, 
•	 professional associations, 
•	 laboratory accreditation organizations, 
•	 health plans and healthcare payers, 
•	 policy groups, and 
•	 patient advocacy organizations. 
What Oversight Currently Exists for Genetic Testing? 
In the United States, laboratory testing devices and kits are subject to FDA 
oversight. When tests are packaged and sold as kits or testing systems to 
laboratories, the FDA requires data collection and evaluation as part of pre-market 
approval or clearance. Currently, however, almost all genetic tests are developed by 
laboratories in-house and are called “home brew” tests, and are not available as 
FDA-approved kits. 
“Home Brew” 
Almost all genetic tests 
are performed by 
laboratories that have 




At present, the Centers for Medicare and Medicaid Services (CMS) provide 
oversight for “home brew” testing by regulating clinical laboratories under the 
Clinical Laboratory Improvement Amendments (CLIA); http://www.cms.hhs.gov/ 
clia. CLIA regulations require laboratories to be responsible for all phases of the 
testing process and focus on laboratory quality systems and in-house analytic 
validation—analytic validity defines the ability of a test to measure accurately and 
reliably what it purports to measure. Currently, clinical cytogenetics—the analysis 
of human chromosomes—is recognized as a specialty area under CLIA, but a 
broader specialty of genetics does not yet exist. As a result, there are no specific 
requirements at the federal level for laboratories performing molecular and other 
types of genetic testing. 
The CDC, in partnership with CMS, has been working to introduce a genetic 
Watch for … 
testing specialty under CLIA to establish specific requirements for laboratories 
performing genetic testing. A Notice of Proposed Rule Making for a genetic 
testing specialty under CLIA is expected in the near future. 
http://www.phppo.cdc.gov/dls/genetics/policy.asp 
“Home Brew” Genetic Tests and the FDA 
To date, the FDA has not regulated “home brew” genetic tests offered by 
laboratories as clinical services, but regulation remains an option. The FDA 
does provide a standard of measurement for regulating certain testing reagents 
as analyte-specific reagents (ASRs). ASRs are used as components in laboratory-
developed (“home brew”) genetic tests and can be sold only to laboratories 
certified under CLIA to perform high-complexity testing. 
It should be noted that FDA review is designed to evaluate a test’s performance, 
including analytic validity, clinical validity, and some aspects of clinical utility. 
Clinical validity defines a test’s ability to detect or predict a particular disorder. 
Clinical utility defines the risks and benefits associated with the introduction of 
a test into practice, including the impact of positive and negative test results on 
health outcomes, cost-effectiveness, and ethical, legal and social issues associated 
with test use. Many points considered in assessing the clinical utility of a test, 
however, are outside the usual purview of FDA and CLIA review. 
FDA News - December 17, 2003… 
FDA Approves Lab Tests for Genetic Clotting Risk - The FDA announced 







How Do States Regulate Genetic Testing? 
Some state agencies regulate laboratories performing genetic testing through 
licensure of personnel and/or facilities. For example, New York requires 
laboratories to submit validation data for approval prior to offering patient testing. 
South Dakota requires that genetic tests be performed in a laboratory that: 
•	 is accredited by a program approved by HHS, such as the College of 
American Pathologists, and 
•	 enrolls in a proficiency-testing program. 
What Private Sector Organizations Are Concerned with Genetic 
Testing? 
Private-sector organizations develop voluntary laboratory and clinical guidelines 
and standards that help to ensure appropriate performance and use of genetic tests. 
Examples of such organizations include: 
•	 American College of Medical Genetics ( .acmg.net
•	 College of American Pathologists (CAP) (http://www.cap.org), 
•	 American Academy of Pediatrics (http://www.pediatrics.org), 




•	 American Society of Human Genetics (http://www.asgt.org), 
•	 National Society of Genetic Counselors (http://www.nsgc.org), 
•	 Association of Molecular Pathologists ( .ampweb.org), and
•	 NCCLS (http://www.nccls.org). 
What is Needed to Ensure the Safety of Genetic Testing? 
In order to ensure the safety and effectiveness of genetic testing in the United 
States, the following needs have been identified: 
•	 development of a standardized approach for evidence-based review of new 
genetic tests to establish safety, efficacy, and cost-effectiveness prior to use 
in routine clinical care, 
•	 ongoing assessment of laboratory practice in genetic testing and 

identification of needs for quality improvement, and

•	 clarification of the roles of regulatory and other government agencies, 
professional organizations, and advocacy groups in genetic test oversight 
and policy development. 
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How is CDC Addressing These Needs? 
The CDC has initiated a number of activities to address these needs: 
Assessing laboratory practice in genetic testing: 
•	 Funding Mt. Sinai School of Medicine to survey the state of practice in 
clinical molecular and biochemical genetic laboratories. Results showed 
that genetic testing was available in a variety of laboratory settings, but 
indicated that specific improvements in quality assurance practices were 
needed to ensure high quality service.5 
•	 Collaboration with Tulane University to assess the variability of result 
reporting for cystic fibrosis and factor V Leiden testing and evaluate the 
usefulness of different report formats to physicians in interpreting genetic 
test results. The findings demonstrated variability in report content, 
including a lack of some information deemed critical by professional 
guidelines and recommendations.6 
•	 Contracting with Duke University School of Medicine and the University 
of California at Los Angeles to pilot-test approaches to developing positive 
controls for genetic tests and help ensure continuous availability of quality 
control materials for the development, validation, performance, and quality 
assurance of genetic tests. 
More information can be found at: http://www.phppo.cdc.gov/dls/genetics/ 
default.asp. 
Evidence-based review and surveillance of genetic tests: 
•	 Establishing a cooperative agreement with the Foundation for Blood 
Research to develop and test a model process for assembling, analyzing, 
and disseminating data on the safety and effectiveness of DNA-based 
genetic tests and testing algorithms. This model process is described by the 
acronym ACCE, which stands for: analytic validity, clinical validity, clinical 
utility and ethical, legal and social implications—the four components 
by which a test is evaluated. Over a 3-year period, five tests for different 
disorders were evaluated, with a goal of facilitating appropriate transition 
of genetic tests from investigational settings to use in clinical and public 
health practice. More information can be found at http://www.cdc.gov/ 
genomics/activities/fbr.htm. See more information about an ACCE review 
in Chapter 4, Public Health Assessment of BRCA1 and BRCA2 Testing for 
Breast and Ovarian Cancer. 
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•	 Conducting a study on the impact of direct-to-consumer marketing. From 
September 2002 to February 2003, the major U.S. provider of genetic 
testing for breast and ovarian cancer susceptibility (BRCA1/2 testing) 
conducted a direct-to-consumer advertising campaign that targeted women 
aged 25-54 and their health care providers in two pilot cities, Atlanta, GA 
and Denver, CO.  The CDC study was intended to assess the impact of the 
advertising campaign on knowledge, attitudes and actions of health care 
providers and consumers related to breast and ovarian cancer risk and 
BRCA testing. 
emerging genetic tests. Human Genome Epidemiology
Am J Epidemiol 2002;156:311-8. 
Suggested Reading On Genetic Test Evaluation: 
Haddow JE and Palomaki GE.  ACCE: A model process for evaluating data on 
. Khoury MJ, Little J, and 
Burke W, eds.  Oxford University Press, Inc. New York, 2003;217-33. 
Burke W, Atkins D, Gwinn M, Guttmacher A, Haddow J, Lau J, et al. Genetic 
test evaluation information needs of clinicians, policy makers and the public. 
More information on genetic testing can be found on the OGDP Web site: 
http://www.cdc.gov/genomics/gTesting.htm 
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Information and Resources 
for Health Care Providers
Michele Reyes, Diane Dunet, Heidi Michels Blanck, and Daurice Grossniklaus 
What is Hemochromatosis? 
Hemochromatosis is a disorder where too much iron accumulates in tissues and 
organs, resulting in iron overloading. If left undiagnosed and untreated, iron 
overloading can cause serious health problems, and can even be fatal. 
In the United States, the majority of hemochromatosis cases are caused by variants 
in the HFE gene, namely C282Y and H63D. A recently-published review of HFE 
genotype frequencies reported that about 9% of the population carries one copy 
of the C282Y mutation and about 0.5% is C282Y homozygous (carries two copies 
of the C282Y mutation). The homozygous genotype is responsible for most cases 
of hemochromatosis,1 but the proportion of people with this genotype who will 
develop the disorder (i.e., the penetrance of the genotype) is unknown. 
Hemochromatosis can be detected with simple blood tests and the treatment 
of choice, phlebotomy (bloodletting), is relatively easy and inexpensive. Early 
diagnosis and treatment of hemochromatosis provides a tremendous opportunity 
to reverse the course of the illness and to prevent the most serious health 
problems of advanced stage hemochromatosis, which are: 
• cirrhosis of the liver, 
• liver cancer, 
• cardiomyopathy (heart muscle disorders), and 
• heart failure. 
More information about hereditary hemochromatosis can be found on the CDC 
Web site at: http://www.cdc.gov/genomics/info/perspectives/hemo.htm. 
Why Is Hemochromatosis a Public Health Problem? 
Research conducted by the CDC and others indicates that primary care 
physicians may lack the knowledge they need to be able to identify patients 
at risk for hemochromatosis.2 These studies have also identified widespread 
misunderstanding among health care professionals about the appropriate 
diagnostic tests and treatments for hemochromatosis. Until the last decade, 
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diagnosis of hemochromatosis most commonly relied on diagnosing the triad of 
cirrhosis, diabetes mellitus, and skin bronzing, and was only confirmed through a 
liver biopsy that uncovered evidence of iron overload. These methods could only 
confirm later-stage hemochromatosis, even though early detection and treatment 
are essential to reducing serious illness and death from this disease. 
When CDC surveyed 2,841 diagnosed hemochromatosis patients, over two-thirds 
(67%) had initially received various multiple diagnoses, including arthritis, liver 
disease, hormonal deficiencies, and diabetes.2 These patients actually did have 
those conditions, but the underlying cause, iron overload, had been missed. 
Patients reported that they saw an average of 5 physicians before receiving a 
diagnosis of hemochromatosis, on average 9.5 years after the onset of symptoms. 
Reducing this time lag by increasing physicians’ awareness of the early symptoms 
of hemochromatosis is clearly an important disease prevention opportunity. 
Is Population Screening Recommended for Hemochromatosis? 
Screening patients to detect and treat chronic diseases early has become an 
important part of medicine and public health.3 The 1996 discovery of the HFE 
variants C282Y H63D responsible for most cases of iron overloading held 
promise for prevention and earlier treatment of the serious health consequences 
of advanced stage hemochromatosis.4 Hereditary hemochromatosis quickly moved 
into the public health spotlight as medical experts and patient support groups 
called for population screening. 
When policy-makers evaluated population-based screening for hereditary 
hemochromatosis in the late 1990s, however, important knowledge gaps were 
identified.5-7 For example, little is known about the clinical course of 
hemochromatosis, the likelihood of complications, or the prevalence of 
asymptomatic iron overload. In addition, reliable information about the prevalence 
and penetrance of the HFE variants is not available. To help fill in these knowledge 
gaps, the National Heart Lung and Blood Institute launched a 5-year study in 
2001 of 100,000 adults in primary care settings.8 The results of this study will 
help policy-makers to understand the benefits and risks of using primary care-
based diagnostic screening for iron overload and hemochromatosis. 
Genetic testing also raises issues related to ethical, legal, and social concerns. 
For more information, please see Chapter 8, Genomics and Public Health: Ethical, 
Legal, and Social Issues. Even when these issues are adequately addressed, 
decisions to institute population screening must also be supported with enough 
scientific evidence of public health effectiveness as well as with enough available 
resources to treat those patients identified through screening. For a population-
based screening program to be effective, it must identify people who are at risk 
of developing the disease. For the program to be cost-effective as well, it should 
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identify only those people who are very likely to develop the disease and are thus 
most likely to benefit from intervention.9 Benefits are proportional to the number 
of cases prevented; therefore, a screening program that fails to identify people 
who will develop the disease—or that identifies many people who would not have 
become ill, even in the absence of intervention—will have a less favorable cost-
benefit ratio. 
Although initial estimates of the percentage of at-risk individuals who would 
actually develop hemochromatosis were high, ranging from 40-70%,10 more recent 
studies have reported clinical estimates ranging from <1-50%.11-14 Inconsistencies 
regarding these estimates persist in the scientific literature. Further studies are 
warranted, including studies designed to find out more about the role of genetic 
and environmental factors. 
At this time, therefore, public health policy-makers have concluded that 
additional information is needed before population-based screening for hereditary 
hemochromatosis can be recommended as a prevention strategy. Currently, 
enhanced case detection among individuals with hemochromatosis symptoms 
and family-based detection are the most practical strategies for early diagnosis and 
treatment of hemochromatosis. 
CDC’s Online Training on Hemochromatosis for Health Care 
Providers 
Physicians and other health-care providers continually face the challenge of 
incorporating the rapidly expanding pool of genetics information and the 
accompanying new technologies into their everyday practices. Continuing 
medical education is required to stay abreast of this exponential growth in 
knowledge. The CDC’s new online course entitled Hemochromatosis: What Every 
Clinician and Other Health Care Professional Needs to Know (http://www.cdc.gov/ 
hemochromatosis/training/index.htm) provides training on: 
•	 the genetics of hemochromatosis, and 
•	 patient care for physicians and other healthcare providers. 
The course was developed by the CDC, in collaboration with hemochromatosis 
experts throughout the United States. The goals of this educational campaign are to: 
•	 promote health by increasing awareness and early detection of 

hemochromatosis, and to 

•	 provide a strategy for health care providers for early intervention in the 
course of the disease. 
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The core curriculum for Hemochromatosis: What Every Clinician and Other Health 
Care Professional Needs to Know consists of six modules and a series of case 
studies. The Web-based self-instructional format was designed to appeal to busy 
practitioners with limited time for training. Course resources integrate research 
findings with clinical practice in an attractive, easy-to-use format. Module and 
course summaries, self quizzes, and a series of interactive case studies allow the 
learner to tailor the course to his/her own learning needs, style and interests. 
Course content focuses on hemochromatosis as one of several diagnostic 
considerations in many clinical settings. Although clinical features, diagnostic 
testing, and patient treatment and management are addressed at length, the 
course avoids prescribing a specific course of physician action. Instead, the 
course integrates concepts related to hemochromatosis, iron overload and genetic 
diseases into everyday practice, and focuses on: 
•	 learning to recognize the early, non-specific symptoms of hemochromatosis 
(e.g. fatigue, joint pain, weakness, weight loss, abdominal pain), 




•	 phlebotomy (bloodletting) treatment to reduce iron overload, and 
•	 counseling hemochromatosis patients about the importance of family-
based detection. 
The course includes colorful, downloadable patient educational materials, as 
well as physician letter templates that can be customized to provide information 
for patients to pass on to family members. Links to additional resources are 
available, including links to referenced articles from the professional literature. 
Information on genetic testing, genetic counseling, and family-based detection are 
also included in the course, together with an easy-to-follow chart suggesting when 
genetic testing may be appropriate for hemochromatosis diagnosis. 
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• Case Studies. 
course. 
to suit their personal information needs. In addition, learners can “book mark” 
segments if desired. 
Continuing Education Credits 







Treatment and Management, 
Family-based Detection, and 
Who Can Take This Course? 
Physicians, health education specialists, nurses and others will benefit from this 
Course Format 
The Web-based format allows convenient, self-paced instruction over the 
Internet using a personal computer. Learners can focus on course components 
their place in the course and return to the Web site to complete the course in 
CEU) through CDC’s online Public Health Training Network. Learners may 
immediately print a Continuing Education Credit Certificate upon completing 
Conclusion 
CDC’s Web-based training course Hemochromatosis: What Every Clinician and 
Other Health Care Professional Needs to Know provides a response to the need for 
easily accessible, reliable information on this genetic disease. The Web-based 
format of the course also meets the need for rapid, individualized learning and 
immediate access to additional resources; this makes it possible to update the 
course easily as new knowledge becomes available. 
In addition, the course also serves as a model of Web-based instruction specifically 
designed for physicians. As new genetic variants are identified, physicians face the 
ongoing challenge of learning, interpreting, and applying new knowledge in their 
practice settings. CDC’s course on hemochromatosis represents a positive step 
towards helping health care providers become prepared to meet these challenges. 
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Genomics Training for 
Public Health Practice:
The Michigan Experience
Janice Bach and Sarah Raup 
Why Does the Public Health Workforce Need Genomics Training? 
Recent scientific discoveries are illuminating the role of genes as risk factors for 
common diseases affecting the public’s health. New applications of genomics 
to medicine are expected to become important tools for health promotion and 
disease prevention. The full benefits of genomics in public health will not be 
realized, however, without a workforce capable of interpreting and applying 
relevant genomic information to the practice setting. 
What Has Been Done to Develop Genomics Training? 
To address the need for a genomically literate workforce, CDC and others have 
initiated efforts to train public health practitioners. Beginning in 2000, the 
Office of Genomics and Disease Prevention (OGDP) and Public Health Practice 
Program Office (PHPPO) convened working groups to outline a set of “Genomic 
Competencies for the Public Health Workforce”. These are available online 
at http://www.cdc.gov/genomics/training/competencies/, and include a set of 
general competencies for all members of the public health workforce and specific 
competencies for each of six professional groups: administrators, clinicians, 
epidemiologists, health educators, laboratorians, and environmental health 
workers. 
In 2001, CDC established three Centers for Genomics and Public Health at 
Schools of Public Health (http://www.cdc.gov/genomics/activities/fund2001.htm), 
which were charged with developing strategies for providing genomics training 
and technical assistance to the public health workforce. 
Simple Training Strategies and Available Courses 
Practical strategies for training the public health workforce in genomics are 
listed in Table 1, along with specific examples used in Michigan. Ideally, local 
expertise should be enlisted as much as possible. While many training materials 
are available from various sources, including books, CD-ROMs and the Internet, 
nothing beats a scheduled, easy-to-attend, in-person session. Genetic counselors, 
medical geneticists, genetic epidemiologists, and other professionals with genetics 
or public health experience should be engaged in training the public health 
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workforce. Existing materials should be shared and utilized as much as possible to 
avoid “reinventing the wheel.” 
Table 1. Overview of Michigan’s Training Strategies 
Strategy Example 
Department of Community Health 
(MDCH) 
Stimulating Interest 
An Introduction to Genomics for Public 
Health Professionals developed by CDC and 
Centers for Genomics and Public Health 
at the Universities of Michigan, North 
3. Increasing Knowledge developed 
by the Michigan Center for Genomics and 
Public Health and delivered to MDCH staff 
4. Strengthening Skills Graduate Summer Session in Epidemiology at 
the University of Michigan School of Public 
Health with scholarships sponsored by the 
Michigan Center for Genomics and Public 
Health 
5. Using Evaluation to Improve Evaluation by organizers, trainers and 
participants 
1. Building a Foundation—Know 
Your Audience 
The Genomics Workgroup at the Michigan 
2. Raising Awareness and 
Carolina, and Washington. 
Six Weeks to Genomic Awareness
Training 
Strategy 1: Building a Foundation—Know Your Audience 
Getting to know your target audience—who they are and what they do—is an 
essential first step in designing training. This might be accomplished through 
both formal and informal channels, such as attending conferences or workshops 
about public health genomics, requesting permission to sit in on staff meetings, 
or holding individual “orientation” meetings with program staff. A working 
relationship with the intended audience serves a two-fold purpose: it provides 
information about specific training needs and acts as a catalyst for raising 
awareness and stimulating interest in genomics among the intended audience. 
Recognize that public health encompasses many disciplines, and that the 
workforce represents professionals from diverse backgrounds. Training should 
be either broad enough to include examples relevant to a range of public health 
professionals, or targeted specifically to a particular group. 
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Example: The Genomics Workgroup 
At the Michigan Department of Community Health, staff members, representing 
a wide range of public health programs, participate in the Genomics Workgroup. 
The group was originally convened in Spring 2000 as a joint effort by the state 
genetics coordinator and chronic disease director. Its mission is to identify and 
facilitate relevant opportunities for the integration of genetics into public health 
science and practice with a special emphasis on chronic disease prevention and 
control. Quarterly meetings serve several purposes, including: 
•	 allowing program staff members who ordinarily would not work together to 
meet and get to know each other, 
•	 providing an opportunity to share updates on state and national genomics 
initiatives, 
•	 serving as a forum for training and education to increase the genomic 
competencies of the MDCH workforce, 
•	 monitoring developments related to family history, screening and 

prevention of adult disorders, 

•	 helping to identify potential funding sources for further genomics 

integration into various programs, and 

•	 allowing for planning and discussion of multi-disciplinary approaches to 
genomics integration. 
The Genomics Workgroup is also used as a “real life” learning laboratory to 
provide the Michigan Center for Genomics and Public Health with feedback that 
can be used to plan training activities. For more information about the role this 
workgroup has played at MDCH, contact genetics@michigan.gov
Strategy 2: Raising Awareness and Stimulating Interest 
Since genomics is not yet a common word in the public health vocabulary, it is 
important to raise awareness and stimulate interest about the potential relevance 
of genomics to various programs among public health practitioners. 
Basic information that will motivate public health practitioners to become 
genomically competent increases the odds that specific training efforts will be 
effective later on. Such introductory efforts may not necessarily give specific 
knowledge or skills to practitioners, but will begin to lay the groundwork for later 
training efforts. 
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“However it is not only the future of genomics that warrants the attention of public 
health education. Because few in the current public health workforce have the level of 
with a framework for understanding the importance of genomics to public health and 
with the ability to apply genomics to the basic public health sciences.” (Who Will 
Keep the Public Healthy? Educating Public Health Professionals in the 21st
IOM, 2003) 
understanding of genomics that is required today, major continuing education efforts 
must be undertaken to ready practicing public health professionals to use genomics 
effectively. Public health education programs and schools must provide their students 
 Century, 
Example: An Introduction to Genomics for Public Health Professionals 
A workgroup consisting of representatives from the CDC and Centers for 
Genomics and Public Health at the University of Michigan, University of North 
Carolina, and University of Washington developed a Web-based presentation 
entitled An Introduction to Genomics for Public Health Professionals. This 
presentation defines basic genetic terms, provides an overview of the current and 
potential role for genomics in public health practice, lists recommended action 
steps, and reviews an example of how genomic information is currently used in 
public health. The presentation is meant to generate interest in and excitement 
about genomics and to motivate public health professionals to participate in 
training opportunities that would further enhance their knowledge and skills. 
An Introduction to Genomics for Public Health Professionals was presented to 
staff at the Michigan Department of Community Health as part of a DNA Day 
Open House in April 2003, that was organized to commemorate the discovery 
of the double helix and promote awareness of genetics in public health. This 
presentation is expected to be available online in Summer 2004 at www.cdc.gov/ 
genomics (http://www.cdc.gov/genomics/GPHP/menu.html), and can be used by 
anyone desiring to raise awareness about and to stimulate interest in genomics 
among public health practitioners. 
Strategy 3: Increasing Knowledge 
Although knowledge about genomics is increasing every day, most public health 
professionals lack an understanding of even the most basic concepts. Practitioners 
also find it difficult to keep up with the growing body of knowledge and to identify 
the most relevant information for their particular work area. Reviewing basic 
genetic terminology, concepts, and associated issues—as well as arming public 
health professionals with tools to keep up with the advances in genomics—is 
therefore an important step in the training process. A workforce familiar with the 
genomics vocabulary and the potential of genomics for public health is more likely 
to engage in projects and activities aimed at integrating genomics into public health. 
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). Plenty of “hands on” activities, encouraging 
Example: Six Weeks to Genomic Awareness 
The Michigan Center for Genomics and Public Health has developed a new 
course, Six Weeks to Genomic Awareness, to familiarize participants with important 
terms, concepts, and issues. The six sessions include: 
• The Human Genome & Heredity 
• Genes in Populations 
• Genetic Testing 
• Gene-Environment Interactions 
• Ethical, Legal, and Social Issues Associated with Genomic Applications 
• Genomic Resources at the State and National Levels. 
The series was piloted at the Michigan Department of Community Health in May-
June 2003. Expert speakers were chosen to present each topic. Seventy program 
staff attended at least one session and 32 attended three or more sessions. 
Participants included staff members from all areas of the health department, 
including epidemiology, laboratory, vital statistics, and chronic disease. The 
Centers for Genomics and Public Health are evaluating Six Weeks to Genomic 
Awareness with the goal of making the entire series available online in Summer 2004. 
Strategy 4: Strengthening Skills 
The final step in ensuring a genomically competent public health workforce is 
to develop practical training opportunities that allow public health practitioners 
to incorporate genomics into the skill sets necessary for their particular job 
functions. Training efforts are needed to address integration of genomics into 
the skill sets of administrators, clinicians, epidemiologists, health educators, 
environmental health specialists, and laboratorians (see http://www.cdc.gov/ 
genomics/training/competencies/
practitioners to apply what they have learned, should be included in these efforts. 
Example: Graduate Summer Session in Epidemiology 
The Michigan Center for Genomics and Public Health provided scholarships 
for several state public health personnel to attend Genetic Epidemiology 
courses offered through the University of Michigan Graduate Summer Session 
in Epidemiology in 2002 and 2003. Although these courses were not tailored 
specifically to practicing public health professionals, they did provide in-depth 
exposure to genetics in the context of epidemiology and allowed practitioners to 
apply what they had learned in problem sets and other exercises. Public health 
attendees, who did not necessarily have a pre-existing background in genetics, 
gave these courses a very favorable review and were grateful for the opportunity to 
participate. 
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Strategy 5: Using Evaluation to Improve Training 
It is very important to measure the effectiveness of existing training courses so that 
they can be improved and new courses can be developed. Building an evaluation 
component into the development of training tools is critical to evaluating and 
modifying training courses and tools effectively. 
Example: Evaluation Data from Six Weeks to Genomic Awareness 
Material Currently 
The Human Genome & Heredity 48% 77% 
54% 70% 
44% 69% 
Gene-Environment Interactions 60% 88% 
ELSI (Ethical, Legal and Social Issues) 55% 65% 
Genomic Resources 40% 80% 
Participants Who Rated Relevance to Their Work Very Good or Excellent, 
Currently and in the Future, as Percent of Those Who Completed Evaluations 
Future 
Genes in Populations 
Genetic Testing 
Lessons Learned 
It is critical to involve representatives from the target audience in planning training 
content and format. Training opportunities should be made as convenient as 
possible for participants. We organized Six Weeks to Genomics Awareness, for 
example, as a brown-bag lunch series at the Michigan Department of Community 
Health. In addition to the foundation that had been laid to increase interest in 
genomics through the DNA Day event and articles in an employee newsletter, the 
convenient location, minimal interference with work schedules, and no cost to 
participants likely contributed to the large attendance at the sessions. 
While strides have been made in addressing the training needs of the public health 
workforce over the past few years, there is still a long way to go in developing a 
genomically competent public health workforce. 
•	 Current training efforts need to be extended to a broader audience. 
Technology should be used to make this happen. For example, Web-based 
distance learning courses are being planned by the Centers for Genomics 
and Public Health. Training resources, including slide presentations and 
other tools, should be shared among those interested in training the public 
health workforce. 
•	 Future training efforts should be tailored to the knowledge and skills sets 
specific to various disciplines of public health, and should also include 
86 
practical opportunities for public health professionals to apply what they 
have learned. 
•	 The effectiveness of training efforts should be assessed. The acquisition 
of new knowledge and skills by public health practitioners and the 
incorporation of this knowledge into public health programs should be 
measured. Coordination and collaboration among a number of public 





Genomics Tools for Public Health
As we continue to learn more about the role that genes play in health and disease, 
public health practitioners will need genomic tools—approaches and products 
based on genomic information that can be used to address public health issues. 
integrated so seamlessly that they are not recognized as “genomic”. 
Chapter 
, emphasizes that genomic tools are 
meant to be immediately relevant, practical, responsive to needs, and somewhat 
proven prior to their promotion and use. New developments in genomics create 
These tools will need to be updated consistently and replaced as knowledge and 
practice evolves. 
three of the public health core functions: 
• assessment, 
• policy development, and 
• assurance. 
Innovative states that produced the initial tools received an overwhelming volume 
of requests, resulting in the initiation of a “toolkit” project designed to collect 
these tools and reduce the burden on the states. The Association of State and 
and collecting tools that have been shown to be effective in public health settings. 
This project was supported with funding from the CDC and developed by a 
Timothy Baker and Kristin L. Peterson-Oehlke 
What are Genomic Tools? 
These tools may be used at the same time as other, more familiar approaches, or 
A good example is family history, which is an amalgam of genetic, environmental, 
behavioral, social, and cultural data that has significant impact on health. 
6, The Family History Public Health Initiative
the need for tools in order to transfer that development into practice effectively. 
Genomic Tools in Practice and The Genomics Toolkit 
Currently, genomic tools (that have been developed and used by several states and 
community-based programs, and exist in one form or another) may address all 
Territorial Health Officials (ASTHO) coordinated this effort to begin identifying 
workgroup of representatives from ASTHO affiliates. The idea was to provide a 
rolling inventory of the best tools to use in program technical assistance. 
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Table 1 lists the groups that were represented on the Genomics Toolkit Project 
Workgroup: 
Table 1. Groups Represented on the Genomics Toolkit Project Workgroup 
ASTHO 
AMCHP Association of Maternal and Child Health Programs 
APHL 
ASTDHPPHE 
Promotion and Public Health Education 
CDC 
OGDP 
Centers for Disease Control and Prevention 
CDD Chronic Disease Directors 
Coalition of State Genetics Coordinators 
National Association of County and Community Health 
National Council of State Legislatures 
Association of State and Territorial Health Officials 
http://www.astho.org/ 
http://www.amchp.org/ 
Association of Public Health Laboratories 
http://www.aphl.org/ 
Association of State and Territorial Directors of Health 
http://www.astdhpphe.org/ 
http://www.cdc.gov 













As part of the Genomics Toolkit, a broad guidance document was developed with 
the purpose of providing assistance for initial program development efforts; this 
document is available online at http://www.genomicstoolkit.org/index.shtml. 
•	  It provides an overview of the role of genomics in health and disease, and 
why genomics is important to public health activities. 
•	  It provides guidance and materials for identifying stakeholders, stimulating 
interest, recruiting an advisory committee, identifying needs and goals, 
developing a work plan and evaluating the process of integrating genomics 
into public health. 
•	  The resource guide section of the toolkit includes information on 
associations and organizations, education and training, funding, planning 
and policy, publications and communications, tools, and presentations. 
In developing this toolkit document, ASTHO collected input from several states. 
Many of the states also provided specific tools used for various applications; these 
tools can be found on their Web sites. The State Snapshots in Table 2 describe 
how those health agencies have applied genomics into public health practice and 
disease prevention programs. 





New York http://www.genomicstoolkit.org/moxie/gettingstarted/ 
forums/newyork.shtml







Table 3 provides a list of specific activities and strategies taken by some states to 
integrate genomics into public health practice and disease prevention programs. 
Table 3. Specific Activities and Strategies for Integrating Genomics into Public 
Health 
Genomics Integration Strategies: Some of the States Using These Tools: 
Models of genomics workgroups 
made up of members from across 
the state health agency 
Michigan, North Carolina 
Assessing needs related to public 
health goals and genomics across 
the state 
Michigan, North Carolina 
Centralized grants writing 
functions that consider genomics 
approaches in the development of 
funding requests
Indiana 
Establishing policies for using 
dried blood spots as source of 
population-based DNA samples
Michigan, New York 
Statewide Genomics Advisory 
Committees that advise on 
genomics across all areas of public 
health policy and practice
North Carolina, Michigan, Utah 
Genetics Taskforce for developing 
public policy related to uses of 
genetic information and technology 
Washington, New York, Michigan 
Using family health history as a 
tool for chronic disease prevention 
Utah 
Planning, developing and delivering 
genomics education to multiple 
audiences, including public health 
Michigan, New York, Washington, North 
Carolina 




http://www  ), 
Genomics Tools We Need, But Don’t Currently Have 
Extensive research in human genomics has created a large and growing body 
of data that must be translated into practical knowledge, so that public health 
practitioners can apply this knowledge to real-life situations. New and existing 
genomic tools must be grounded in scientific data, and must be able to 
accommodate new knowledge as it becomes available. 
Public health agencies need guiding principles, processes and strategies to help 
understand and define the role of genomics in public health. Public health 
workers also need education to equip them with the knowledge and skills to help 
interpret genomic information for the general public. See Chapter 12, Genomics 
Training for Public Health Practice: The Michigan Experience, for more information. 
Genomics has entered the lexicon of popular culture, and increasing public 
understanding of this area is important to build confidence and to avoid risks 
from inappropriate use, as well as to let more people know about the relevant 
benefits. As genomics increasingly enters health practice, health professionals 
must be informed, and must also be able to inform the public accurately, using 
tools that are reliable. Each community will require tools, matched to local 
population needs, which will allow policy makers to support genomics in practice. 
How Will New Tools Be Developed? 
New tools will be developed (and old tools refined through use in other settings) 
in the context of practice in state and local public health agencies and in 
collaboration with academic partners, such as the Centers for Genomics in Public 
Health (http://www.cdc.gov/genomics/activities/fund2001.htm). These centers are 
housed within the following schools of public health at their parent universities: 
• North Carolina ( .sph.unc.edu/nccgph/
• Michigan (http://www.sph.umich.edu/genomics/index.html ), and 
• Washington (http://depts.washington.edu/cgph/ ). 
These centers have a primary responsibility for responding to program 
development needs at the state and community levels, and thus finding, refining, 
applying, and using tools that directly support those needs. Each center has the 
capacity and resources to assess needs and develop tools with their practicing 
partners. 
In 2002, the Chronic Disease Directors association convened a Chronic Disease 
Summit at CDC to focus on the emerging role of genomics in chronic disease 
prevention (http://www.chronicdisease.org/genomics___chronic_disease_ 
con.html). This meeting focused on disease-specific issues, with emphasis 
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on specific tools/priorities for states. In response to recommendations from 
the summit, the National Center for Chronic Disease Prevention and Health 
Promotion (NCCDPHP, www.cdc.gov/nccdphp) began development of state-based 
capacity through funding to four states (Michigan, Minnesota, Oregon, and Utah) 
for integrating genomics into chronic disease prevention programs. The purpose 
of this program is to develop genomics leadership and coordination within state 
agencies to allow planning, development, integration and evaluation of genomics 
as a tool for chronic disease prevention and health promotion. Documenting 
the activities, experiences and achievements of these states will produce model 
processes and applications that should be useful to other states. See Chapter 
14, State Capacity Grants for Integrating Genomics into Chronic Disease Prevention 
Programs, for more information. 
Thinking Genomically—the Vision for the Future 
Thinking genomically means including genomics as another factor that is routinely 
considered when addressing any public health problem, and applying genomic 
information when it makes sense to achieve public health goals. In the future, 
genomics will be integrated into the fabric of public health activities as seamlessly 
and universally as epidemiology is today. 
The time will soon be upon us when it is impossible to consider any health or 
medical condition without considering its genomic basis. In the not-too-distant 
future, a complete approach to any public health problem will include an 
assessment of the role of human genes in the life processes underlying health and 
disease. The tools, approaches, and capacity that we develop today will form the 




State Capacity Grants for 
Integrating Genomics into Chronic 
Disease Prevention Programs
Jennifer Singh and Catherine A. Hutsell 
Introduction 
In order to integrate genomics into a wider of range of disease control and 
prevention programs, state and community health agencies are recognizing the 
Chronic Disease Prevention and Health Promotion (NCCDPHP), CDC, addressed 
j
Michigan, Minnesota, Oregon and Utah 
Genomics and Chronic Disease Prevention Programs 
• 
infectious and other diseases, 
• enhance planning and coordination for integrating genomics into core state 
environmental health), and 
• 
interactions to enhance chronic disease prevention. 
j
• Capacity and Infrastructure: 
Develop state and local leadership capacity and infrastructure for 
integrating genomics into public health. 
need to expand existing genetics expertise in maternal and child health and 
newborn screening to agency-wide capacity. In July 2003, the National Center for 
this need by establishing cooperative agreements with state health departments in 
Michigan, Minnesota, Oregon and Utah to strengthen programs for genomics and 
chronic disease prevention. The purpose of this pro ect is to assist states in developing 
or expanding capacity for genomics leadership and to promote coordination. 
The overall goals of this five-year project are to: 
integrate genomics and family history into ongoing and new population-
based strategies for identifying and reducing the burden of specific chronic, 
public health specialties (such as epidemiology, laboratory activities, and 
facilitate use of family history and new knowledge about gene-environment 
State Work Plans 
The four states selected to participate in the Genomics and Chronic Disease 
Prevention Program identified the following common ob ectives in their work plans: 
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•	 Training and Technical Assistance: 
Educate the pubic health workforce, policy makers and the general public 
about the role of genomics in public health. 
•	 Data Collection: 
Develop and implement population-based assessments using existing 
surveillance and data systems. 
•	 Assessment and Use of Genomics Tools: 
Coordinate the use and evaluation of targeted genomic risk assessment 
strategies and family history tools. 
Progress to Date 
In January 2004, the first Genomics Program Directors Meeting was held in 
Atlanta to bring together representatives from the four funded states, CDC 
program staff and directors of the three CDC-funded Centers for Genomics and 
Public Health to discuss progress, plans and potential collaboration. At that time, 
the states also described specific activities initiated in the first four months of the 
project that would build on each state’s unique experiences and capacity. Specific 
year-one state activities reported at the meeting are highlighted below. 
Michigan 
The Michigan Department of Community Health (MDCH) has created a detailed 
work plan for integrating genomics capacity across the spectrum of public health 
practice. The MDCH has initiated an array of training activities, such as: 
•	 partnering with the University of Michigan Center for Genomics and 
Public Health to plan and conduct an informational session for Michigan 
legislators, and to begin development of a “Cancer Genetics” training 
module, 
•	 initiating collaboration with Michigan State University to develop sessions 
on genomics and chronic disease for “Frontiers in Science” teacher 
education series, 
•	 developing and pre-testing family history questions for a behavioral 
risk factor survey, and studying the feasibility of adding family history 
information to the Cancer Registry, and 
•	 participating in the MDCH Cardiovascular Health Task Force, Diabetes 
Primary Prevention Project, and Primary Care Systems/Barriers to 
Prevention Working Group. 
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Minnesota 
The Minnesota Department of Health (MDH) is addressing the rapidly expanding 
need for genomics leadership in Minnesota’s public health programs, especially in 
the areas of policy, planning and intervention. Minnesota’s initial activities have 
focused on building relationships, communication and capacity, including:  
• establishing relationships by participating in existing groups to provide 
genomics perspectives, such as:

Diabetes Program Steering Committee,

Cardiovascular Health Planning Committee, and

Comprehensive Cancer Control Planning;

•	 creating a Genomics Team by recruiting members from across the agency 
and establishing roles, procedures and a work plan; and 
•	 developing a training agenda for the agency after evaluating the CDC 
and the National Coalition for Health Professional Education in Genetics 
(NCHPEG) genomic competencies. 
Oregon 
The Oregon Department of Human Services (ODHS) has proposed a program that 
will strengthen Oregon’s public health capacity to address current and emerging 
genomics issues, ultimately improving the health and well being of individuals and 
families impacted by heritable conditions, including common chronic diseases. 
Project activities conducted by the ODHS Office of Family Health, in collaboration 
with the ODHS Office of Disease Prevention and Epidemiology, include: 
•	 acquiring new agency expertise by hiring a genetic epidemiologist and 
genetic program coordinator, 
•	 partnering with the University of Washington Center for Genomics and Public 
Health to develop a model assessment process for integrating genomics, 
•	 completing a comprehensive literature review of diabetes and genetics, 
•	 collecting existing program assessment materials and tools and initiating 
the development of a conceptual model of the Diabetes Program, and 
•	 identifying the structure of and potential members for the Agency Genomic 
Coordinating Team, which will enhance cross-program communication and 
coordination between the Genetics program and Health Promotion and 
Disease Prevention Programs. 
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Utah 
The Utah Department of Health (UDOH) is developing public health leadership 
capacity and infrastructure to better integrate genomics into public health practice, 
particularly in chronic diseases. Since becoming fully staffed, the UDOH has been 
engaged in several activities, such as: 
•	 establishing an Internal Working Group of approximately 35 public health 
professionals that has met and established subcommittees for policy, data 
and surveillance, and education and training, 
•	 convening the External Chronic Disease Standing Subcommittee of the 
State Genetics Advisory Committee, 
•	 revising the portion of the state genetics plan relevant to chronic disease, 
•	 meeting with chronic disease program managers to identify appropriate 
objectives for their state chronic disease funding applications, and 
•	 documenting and reviewing experience of the Utah Health Family Tree 
Program, to gain a historical perspective and recommend a new family 
history-based approach. 
Next Steps 
Genomics Program Directors Meeting Report 
The four states are collaborating with CDC in the development and publication of 
a report that will summarize the results of the first Genomics Program Directors 
Meeting, held in January 2004.  This report will describe the logic model 
developed by the states to guide genomics program efforts in both funded and 
non-funded participating states; it will also identify short-, medium- and long-
term goals, as well as a description of the shared vision for integrating genomics in 
chronic disease and other public health programs. 
Forthcoming Year-One Activities 
Indicators for milestones that demonstrate progress over the next three to five 
years for diseases with promising genomic public health applications (e.g., 
cardiovascular disease, breast cancer and diabetes) will be identified this year 
through a series of conference calls between the states and CDC. Each state 
will also continue to build capacity by developing, hiring and/or training full-
time genomics positions and developing internal and external genomics work 
groups. As part of the training agenda, the states plan to conduct a training needs 
assessment and an evaluation of existing training programs within the next year. 
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Genomics sessions have also been scheduled at the 2004 statewide chronic 
disease conferences, as well as at other state and local public health meetings. 
Year-one data collection efforts will include feasibility studies of statewide 
registries, such as a statewide hereditary cancer registry, and pilot studies to test 
the usability of archived NBS dried blood spot cards. 
Individual State Genomics Plans 
The following table provides Web links to individual state genomics plans: 
Table 1. State Genomics Plans 
Michigan 










Internet Resources for Genomics 
and Disease Prevention
Jennifer Singh and Kate Reed 
The Internet offers many resources that may be useful to national, state and local 
public health professionals interested in learning more about genomics and public 
health. This chapter provides a selected list of sites that offer starting points; 
a longer list is available in the online version of this report, available at http: 
//www.cdc.gov/genomics/activities/ogdp/2003.htm. Many other online resources 
are available; this list is only a snapshot of some that may be useful for integrating 
genomics into health promotion and disease prevention programs. Please refer to 
the disclaimer at the end of this chapter. 
CDC Office Of Genomics And Disease Prevention (OGDP) 
http://www.cdc.gov/genomics/ 
This site provides information about ways that human genomic discoveries can be 
used to improve health and prevent disease. It provides links to activities in public 





A weekly update on the impact of human genetic research on disease 
prevention and public health. To receive notification of this update by 
e-mail, please send the following message: 
To: listserv@listserv.cdc.gov 
Subject: (leave blank) 
Message: subscribe genetics 




On the Highlights page on the OGDP Web site, each Public Health 
Perspective focuses on a single topic and provides information relevant to 
public health practice. Past topics include family history, BRCA1/2 testing, 
obesity, and others. 
•	 Genomics and Disease Prevention Information System (GDPInfo): 
http://www2a.cdc.gov/genomics/GDPQueryTool/default.asp 
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The GDPInfo query tool allows you to define your search of the OGDP 
Web site with a combination of genes, diseases/conditions, topics and 
other factors. The search provides a list of all related documents and links 
to other sites. 
Human Genome Project 
Human Genome Project Information from the US Department of Energy: 
http://www.ornl.gov/sci/techresources/Human_Genome/home.shtml 
The U.S. Department of Energy and the National Institutes of Health formally 
initiated the Human Genome Project in 1990. The project originally was planned 
to last 15 years, but rapid technological advances allowed it to be completed in 
2003. This site provides an overview of the Human Genome Project and links to 
other sites. 
National Human Genome Research Institute (NHGRI): 
http://www.nhgri.nih.gov/ 
The NHGRI supports genetic and genomic research, investigation into the ethical, 
legal and social implications surrounding genetics research, and educational 
outreach activities in genetics and genomics. 
The Human Genome —A Guide to Online Information Resources from the 
National Library of Medicine: 
http://www.ncbi.nlm.nih.gov/genome/guide/human/ 
A comprehensive site that provides information and links to information about 
specific genes and genetic diseases. 
Selected articles: 




Articles from Annals of Internal Medicine 1 April 2003 Volume 138 
Issue 7 
•	 Primer on Medical Genomics: History of Genetics and Sequencing of the 
Human Genome: 
http://www.mayo.edu/proceedings/2002/aug/7708mgl.pdf 




•	 New England Journal Of Medicine: Genomic Medicine Series (2002-2003): 
http://content.nejm.org/misc/genmed.shtml 
The full text of all thirteen articles in this series is available free to all users. 
Genomic Research 
Human Genetics and Medical Research: 
http://history.nih.gov/exhibits/genetics/ 
An online exhibit for the public providing information about the use of genetics in 
medicine sponsored by the National Institute of Health (NIH), 
http://www.nih.gov/ 
Genes and Populations: 
http://www.nigms.nih.gov/news/science_ed/genepop/ 
A series of questions and answers for patients considering participation in research 
studies from the National Institute of General Medical Sciences, 
http://www.nigms.nih.gov/ 
August 2003 Issue Brief “Applied Public Health Research in Genomics”: 
http://www.astho.org/pubs/AppliedPHResearchinGeneticsIssueBrief.pdf 
An issue brief released by ASTHO that outlines the importance of applied public 
health research in genomics and the types of research needed, the ethical, legal, 
and social issues that accompany this type of research, current public health 




A publicly-funded medical genetics information resource developed for physicians, 
other healthcare providers, researchers, and others needing information about 
existing genetic tests. This site includes expert-authored reviews, directories of 
laboratories and clinics offering genetic tests, and educational materials. 
National Academy of Sciences: Human Gene Testing: 
http://www.beyonddiscovery.org/content/view.article.asp?a=239 
A summary of human genetic testing that ranges from the unraveling of the nature 
of the gene to the social dilemmas posed by genetic testing. 
Understanding Gene Testing: 
http://press2.nci.nih.gov/sciencebehind/genetesting/genetesting00.htm 
Illustrates what genes are, explains how mutations occur and how they are 
identified within genes, and discusses the benefits and limitations of gene testing 
for cancer and other disorders. Provided by the National Cancer Institute. 
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Family History 
Genetics & Your Practice: 
http://www.marchofdimes.com/gyponline/index.bm2 
A resource that provides practical information and resources to assist the busy 
professional in integrating genetics into their patient care. 
•	 Family Health and Social History: (Link same as above) 
A timesaving method of family history taking and sample family history 
questionnaires. 
The Genetic Family History in Practice newsletter for health care professionals 
from NCHPEG’s Family History Working Group: 
http://www.nchpeg.org/newsletter/newsletter.asp 
Your Family History: 
http://genetics.faseb.org/genetics/ashg/educ/007.shtml 
A family history tool developed through the collaboration with the American 
Society of Human Genetics, the National Society of Genetic Counselors and 
Genetic Alliance. 
Genes and Diseases 
Disease InfoSearchTM: 
http://www.geneticalliance.org/DIS/index.html 
A tool to assist in finding specific and quality information about genetic 




An online publication of expert authored disease reviews from GeneTests, 
http://www.geneclinics.org/ 
Genetics Home Reference: 
http://ghr.nlm.nih.gov/ghr/template/Home.vm 
Provides consumer information about genetic conditions and associated genes. 
From the National Library of Medicine, http://www.nlm.nih.gov/nlmhome.html 
Office of Rare Diseases (ORD):   
http://rarediseases.info.nih.gov/ 
This Web site provides information about ORD-sponsored scientific activities, 
an ORD cosponsored genetic and rare diseases information center, and a portal 
to databases that provide information on major topics of interest in rare diseases 
research. 
104 
Genes and Diseases: 
http://www.ncbi.nlm.nih.gov/books/bv.fcgi?call=bv.View..ShowSection&rid=gnd 
A collection of articles that discuss genes and the diseases that they cause from the 
National Center for Biotechnology Information (NCBI), 
http://www.ncbi.nlm.nih.gov/ 
Online Mendelian Inheritance of Man (OMIM): 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM&cmd=Limits 
A database providing a catalog of human genes and genetic disorders authored 
by the Johns Hopkins University Medical School and developed by the National 
Center for Biotechnology Information (NCBI), http://www.ncbi.nlm.nih.gov/ 
at the National Library of Medicine, http://www.nlm.nih.gov/ 
Genes and Diseases: Cancer 
National Cancer Institute: 
http://www.cancer.gov/ 
•	 Cancer Genetics: 
http://www.cancer.gov/cancerinfo/prevention-genetics-causes/genetics 
A comprehensive list of cancer genetics information ranging from general 
to specific cancer information, policy, and cancer genetics research and 
information. 
Genes and Diseases: Birth Defects 
March of Dimes Birth Defects Foundation: 
http://www.marchofdimes.com/home.asp 
A not-for-profit organization with the mission to improve health of babies by 
preventing birth defects and infant mortality. 




National Birth Defects Prevention Network: 
http://www.nbdpn.org/ 
A group with the mission to establish and maintain a national network of state 
and population-based programs for birth defects surveillance and research to 
assess the impact of birth defects upon children, families, and health care; to 
identify factors that can be used to develop primary prevention strategies; and to 
assist families and their providers in secondary disabilities prevention. 
Genes and Diseases: Newborn Screening 
National Newborn Screening and Genetics Resource Center (NNSGRC): 
http://genes-r-us.uthscsa.edu/index.htm 
Provides information and resources in the area of newborn screening and genetics 
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to benefit health professionals, the public health community, consumers, and 
government officials: 
• a report on the characteristics of state NBS programs, 
• state newborn screening program resources, and 
• resources for state genetics planning. 
Association of Public Health Laboratories (APHL) Newborn Screening and 
Genetics Program: 
http://www.aphl.org/Newborn_Screening_Genetics/index.cfm 
March of Dimes Newborn Screening Recommendations: 
http://www.marchofdimes.com/professionals/580_4043.asp 
Public Health Ethical, Legal and Social Issues (PHELSI) 
The U.S. Department of Energy Human Genome Project: 
http://www.ornl.gov/sci/techresources/Human_Genome/elsi/elsi.shtml 
An educational and informational site about the human genome project. This is a 
publication of the U.S. Department of Energy Human Genome Program. 
Genetics Education and Counseling Program: 
http://www.pitt.edu/~edugene/resource 
A public health initiative for community and professional education and 
awareness on genetics. This Web site is sponsored by the University of Pittsburgh. 
Public Health Genetics from University of Sheffield-School of Health and 
Related Research (Scharr): 
http://www.shef.ac.uk/~scharr/publich/research/genetics/index.html 
A catalogued series of articles on various topics including technical issues, genetic 
testing in the workplace, and experiences of individuals affected by genetic 
diseases from the U.K. 
Michigan Centers for Genomics and Public Health: 
http://www.sph.umich.edu/genomics/index.html 
The Michigan Center for Genomics & Public Health seeks to integrate genomic 
discoveries into public health practice, with consideration of the ethical, legal, and 
social issues associated with the application of these discoveries, as well as the 
involvement of the community at large. 
Genetics and Ethics Page: 
http://genethics.ca/index.html 
A clearinghouse for information on the social, ethical and policy issues associated 
with genetic and genomic knowledge and technology. 
106 
Policy 
National Conference of State Legislatures (NCSL) Genetic Technologies Project 





A group commissioned to provide state legislators and other policymakers with 
objective, comprehensive, and scholarly information from a non-partisan source to 
facilitate the drafting of sound genetics-related legislation. 
Secretary’s Advisory Committee on Genetics, Health and Society: 
http://www4.od.nih.gov/oba/sacghs.htm
 “A forum for expert discussion and deliberation and the formulation of advice and 
recommendations on the range of complex and sensitive medical, ethical, legal 
and social issues raised by new technological developments in human genetics.” 
Genetics and Public Policy Center: 
http://www.dnapolicy.org/index.jhtml 
Information on genetic technologies and genetic policies for the public, media and 
policymakers. The Genetics and Public Policy Center is funded through a grant 
from The Pew Charitable Trusts. 
Public Health Resources 
Genomics: A Guide for Public Health: 
http://www.genomicstoolkit.org/index.shtml 
A guide to help state public health agencies integrate genetics into their programs. 
This guide provides integration strategies, tools for needs assessment, priority 
setting guides, snapshots of current integrated programs, many resources, and 
much more. 
Coalition of State Genetic Coordinators: 
http://www.stategeneticscoordinators.org/index.html 
An organization of state and territorial genetics coordinators and others who 
support the mission to promote core public health functions as they apply to 
genetics. 
Genomics and Chronic Disease Summit Report, 2002: 
http://www.chronicdisease.org/Genomics_Summit_Report.pdf 
A report from the Association of State and Territorial Chronic Disease Directors. 
Harnessing Genetics to Prevent Disease & Improve Health: 
http://www.prevent.org/publications/GeneticsReport.pdf 
A guide to help states shape genetics policies for the purpose of advancing 
individual and collective health. The report highlights recommendations for 
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policymakers to address the social, legal and ethical implications of genetics in 
their states. 
Centers for Genomics and Public Health: 
http://www.cdc.gov/genomics/activities/fund2001.htm 








•	 University of North Carolina Center for Genomics and Public Health, 
the Genomics Revolution and Public Health: 
http://www.sph.unc.edu/nciph/phgenetics/index.htm 
The WHO Genetics Programme: 
http://www.who.int/genomics/en/ 
Information about activities undertaken by the WHO Human Genetics Program 
to help control the “most common hereditary diseases and those having a genetic 
predisposition.” 
Educational Resources 
National Coalition for Health Professional Education in Genetics (NCHPEG): 
http://www.nchpeg.org/ 
A national effort to promote health professional education and access to 
information about advances in human genetics: 
•	 Genetic Resources on the Web (GROW), 
•	 Genetic Family History Resources, and 
•	 Educational Resources. 
Genetic Educational Materials Database (GEMS): 
http://www.gemdatabase.org/GEMDatabase/index.asp 
Searchable listing of public health genetics policy documents and clinical genetics 
educational materials from the National Newborn Screening and Genetics 
Resource Center (NNSGRC). 
OGDP List of Training Tools: 
http://www.cdc.gov/genomics/training/tools.htm  
A list of available training tools, courses, and multi-media educational materials 
designed to assist public health professionals and educators integrate genomics 
into public health practice. 
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Disclaimer:
constitute an endorsement of these organizations or their programs by CDC or 
does not mean there are no other useful resources available. The CDC is not 
these links. Note that some links may become invalid over time. 
 The CDC Office of Genomics and Disease Prevention makes this 
information available as a public service only. Providing these links does not 
the federal government, and none should be inferred. Exclusion of information 
responsible for the content of the individual organization Web pages found at 
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